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Abstract
Randomised controlled trial and parallel economic 
evaluation of conventional ventilatory support versus 
extracorporeal membrane oxygenation for severe 
adult respiratory failure (CESAR)
GJ Peek,1* D Elbourne,2 M Mugford,3 R Tiruvoipati,1 A Wilson,4 E Allen,2 
F Clemens,2 R Firmin,1 P Hardy,2,5 C Hibbert,6 N Jones,1 H Killer,1 M 
Thalanany3 and A Truesdale2
1Department of Cardiothoracic Surgery, Glenfield Hospital, Leicester, UK
2Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK
3Health Economics Group, School of Medicine Health Policy and Practice, University of East Anglia, 
Norwich, UK
4Department of Health Sciences, University of Leicester, UK
5Clinical Epidemiology and Biostatistics Unit, Royal Children’s Hospital, Melbourne, Australia
6School of Health and Related Research, University of Sheffield, UK
*Corresponding author
Objectives: To determine the comparative 
effectiveness and cost-effectiveness of conventional 
ventilatory support versus extracorporeal membrane 
oxygenation (ECMO) for severe adult respiratory 
failure.
Design: A multicentre, randomised controlled trial 
with two arms.
Setting: The ECMO centre at Glenfield Hospital, 
Leicester, and approved conventional treatment centres 
and referring hospitals throughout the UK.
Participants: Patients aged 18–65 years with severe, 
but potentially reversible, respiratory failure, defined 
as a Murray lung injury score ≥ 3.0, or uncompensated 
hypercapnoea with a pH < 7.20 despite optimal 
conventional treatment.
Interventions: Participants were randomised to 
conventional management (CM) or to consideration of 
ECMO.
Main outcome measures: The primary outcome 
measure was death or severe disability at 6 months. 
Secondary outcomes included a range of hospital 
indices: duration of ventilation, use of high frequency/
oscillation/jet ventilation, use of nitric oxide, prone 
positioning, use of steroids, length of intensive care 
unit stay, and length of hospital stay – and (for ECMO 
patients only) mode (venovenous/veno-arterial), 
duration of ECMO, blood flow and sweep flow.
Results: A total of 180 patients (90 in each arm) 
were randomised from 68 centres. Three patients in 
the conventional arm did not give permission to be 
followed up. Of the 90 patients randomised to the 
ECMO arm, 68 received that treatment. ECMO was not 
given to three patients who died prior to transfer, two 
who died in transit, 16 who improved with conventional 
treatment given by the ECMO team and one who 
required amputation and could not therefore be 
heparinised. Ninety patients entered the CM (control) 
arm, three patients later withdrew and refused follow-
up (meaning that they were alive), leaving 87 patients 
for whom primary outcome measures were available. 
CM consisted of any treatment deemed appropriate 
by the patient’s intensivist with the exception of 
extracorporeal gas exchange. No CM patients received 
ECMO, although one received a form of experimental 
extracorporeal arteriovenous carbon dioxide removal 
support (a clear protocol violation). Fewer patients 
in the ECMO arm than in the CM arm had died or 
were severely disabled 6 months after randomisation, 
[33/90 (36.7%) versus 46/87 (52.9%) respectively]. This 
equated to one extra survivor for every six patients 
treated. Only one patient (in the CM arm) was known 
to be severely disabled at 6 months. Patients allocated 
to ECMO incurred average total costs of £73,979 
compared with £33,435 for those undergoing CM 
(UK prices, 2005). A lifetime model predicted the cost 
per quality-adjusted life-year (QALY) of ECMO to be 
£19,252 (95% confidence interval £7622 to £59,200) 
at a discount rate of 3.5%. Lifetime QALYs gained were Abstract
iv
10.75 for the ECMO group compared with 7.31 for the 
conventional group. Costs to patients and their relatives, 
including out of pocket and time costs, were higher for 
patients allocated to ECMO.
Conclusions: Compared with CM, transferring 
adult patients with severe but potentially reversible 
respiratory failure to a single centre specialising in the 
treatment of severe respiratory failure for consideration 
of ECMO significantly increased survival without severe 
disability. Use of ECMO in this way is likely to be cost-
effective when compared with other technologies 
currently competing for health resources.
Trial registration: Current Controlled Trials 
ISRCTN47279827.DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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Executive summary
Background
Severe respiratory failure has a high mortality in 
adult patients despite recent advances in intensive 
care. The fundamental dichotomy of conventional 
treatment of these patients is that positive pressure 
ventilation is dangerous when high concentrations 
of oxygen (fractional inspired oxygen, FiO2) and 
large tidal volumes/high airway pressures are used, 
as such ventilation causes ventilator-induced lung 
injury, which decreases survival. The paradox is 
that the sickest patients with the severest lung 
injury require the highest ventilator settings and 
are most at risk of ventilator-induced lung injury. 
Extracorporeal membrane oxygenation (ECMO) 
uses cardiopulmonary bypass technology to 
support gas exchange in the intensive care unit 
(ICU) allowing ventilator settings to be reduced, 
thereby giving the lungs a chance to recover. 
Although ECMO has been proven in a randomised 
controlled trial (RCT) to increase survival in severe 
neonatal respiratory failure, its use in adults has 
not been similarly validated. 
Objectives and entry 
criteria
CESAR (Conventional ventilation or ECMO for 
Severe Adult Respiratory failure) was a nationwide 
UK RCT whose primary hypothesis was that ECMO 
will improve survival without severe disability at 
6 months for adults (18–65 years) with severe 
(Murray lung injury score ≥ 3.0 or pH < 7.2) but 
potentially reversible respiratory failure and will be 
cost-effective. 
Funding
The trial was funded by the National Institute 
for Health Research (NIHR) Health Technology 
Assessment (HTA) programme and the clinical 
treatment costs were funded by the NHS via the 
National Specialist Commissioning Advisory Group 
for England and Wales and through the Scottish 
Executive. 
Setting
One hundred and three hospitals obtained ethics 
committee approval to participate, and trial entry 
was also allowed from centres that did not have 
ethics committee approval as long as they agreed to 
transfer the patient to a centre with approval under 
the Emergency Inclusion Protocol. 
Contraindications
Contraindications to trial entry were high 
pressure/high FiO2 ventilation (> 30 cm H2O 
of peak inspiratory pressure) and/or high FiO2 
(> 0.8) ventilation for more than 7 days; signs of 
intracranial bleeding; any other contraindication to 
limited heparinisation; or any contraindication to 
continuation of active treatment. 
Outcome measures
The primary outcome measure was death or 
severe disability at 6 months. Severe disability was 
defined as patients being unable to wash or dress 
themselves and confined to bed. Primary analysis 
was by intention to treat.
Patients and methods
Between July 2001 and August 2006 enquiries 
were made about 766 potentially eligible patients 
from 148 centres. One hundred and eighty of these 
were randomised from 68 centres, 90 in each arm. 
Patients were randomised via a telephone call to 
an automated independent central randomisation 
service either to continued conventional treatment 
or to transfer to Glenfield Hospital in Leicester for 
consideration of ECMO; to ensure close balance 
between treatment groups for minimisation was 
used. After the first patient was allocated treatment 
using simple randomisation, the next patient to 
enter the trial was allocated to whichever treatment 
group improved the overall balance according to a 
pre-selected set of baseline minimisation criteria, Executive summary
x
namely type of centre [conventional treatment 
centre (CTC) or referral hospital (RH)]; age (18–
30, 31–45, 46–65 years); hours of high pressure 
and/or high FiO2 ventilation (0–48, 49–168); mode 
of trial entry (i.e. hypoxic/hypercarbic); diagnostic 
group [pneumonia, obstetric acute respiratory 
distress syndrome (ARDS), trauma including 
surgery within previous 24 hours, other ARDS, and 
other]; and numbers of organs failed (one or two, 
or three or more) where organ failure was a Sepsis-
related Organ Failure Assessment (SOFA) score 
for that organ of greater than 2. If the patients 
were randomised to conventional management 
(CM) and were in a CTC, they remained in the 
CTC. CTCs were large ICUs that were felt by the 
local ICU network lead to provide all necessary 
treatment modalities or, where local ICU networks 
did not exist, were those units with more than 350 
admissions per year that could provide pressure 
controlled ventilation and haemofiltration. Smaller 
hospitals that did not fulfil these criteria were 
classified as RHs. One hundred and forty-eight 
patients entered the trial from CTCs and 32 from 
RHs, which included patients entering under 
the Emergency Inclusion Protocol. If a patient 
in an RH drew conventional treatment they were 
transferred by the ECMO transport team to the 
nearest CTC with a bed available. All patients 
who drew ECMO were transferred by the same 
team to Glenfield Hospital for consideration 
of ECMO. The mean (standard deviation, SD) 
age at trial entry was 39.9 (13.4) years in the 
ECMO arm and 40.4 (13.4) years in the CM arm. 
Primary diagnosis at trial entry was (ECMO/CM) 
pneumonia 56/53, other ARDS 25/26, trauma or 
surgery within 24 hours 5/7 and other 4/4. The 
number of organs failed was (ECMO/CM) one or 
two in 62/63 patients and more than three in 28/27 
patients. Median (interquartile range) duration 
of ventilation was 35.0 (17.3–104.5) hours in the 
ECMO arm and 37.0 (15.5–101.5) hours in the 
CM arm, 28.5 (17.0–69.3) of these hours were at 
high pressure/high FiO2 in the ECMO arm and 28.0 
(12.0–88.0) in the CM arm. Eighty-five patients 
entered the ECMO arm for hypoxia (Murray 
score ≥ 3.0) and 87 entered the conventional arm, 
the remainder entered because of hypercarbia 
(pH < 7.2). The mean (SD) Murray score was 
(ECMO/CM) 3.5 (0.6)/3.4 (0.3). The median (IQR) 
arterial oxygen pressure (PaO2)/FiO2 ratio (ECMO/
CM) was 73 (57.5–87)/70.5 (60–88) mmHg. All 85 
patients in the ECMO arm who entered because 
of hypoxia fulfilled the American–European 
consensus definition of ARDS. In the conventional 
arm, 87 patients entered based on hypoxia, 84 
fulfilled the ARDS criteria and two the acute lung 
injury criteria.
Results
Of the 90 patients randomised to the ECMO arm, 
68 received that treatment. ECMO was not given to 
three patients who died prior to transfer, two who 
died in transit, 16 who improved with conventional 
treatment given by the ECMO team and one who 
required amputation and could not therefore 
be heparinised. Ninety patients entered the CM 
(control) arm, three patients later withdrew and 
refused follow-up (meaning that they were alive), 
leaving 87 patients for whom primary outcome 
measures were available. CM consisted of any 
treatment deemed appropriate by the patient’s 
intensivist with the exception of extracorporeal 
gas exchange. The low volume ventilation strategy 
from the ARDS Network (ARDSNet) study was 
recommended. No CM patients received ECMO, 
although one received a form of experimental 
extracorporeal arteriovenous carbon dioxide 
removal support (a clear protocol violation). 
Fewer patients in the ECMO arm than in the CM 
arm had died or were severely disabled 6 months 
after randomisation, [33/90 (36.7%) versus 46/87 
(52.9%) respectively; relative risk (RR) = 0.69 [95% 
confidence interval (CI) 0.50 to 0.97]; p = 0.030]. 
This equated to one extra survivor for every six 
patients treated. Only one patient (in the CM arm) 
was known to be severely disabled at 6 months.
Economic evaluation
Previous studies of ECMO had not estimated 
the additional costs or the consequences of 
treatment. However, the high costs of intensive 
care and changes in resource use and quality of 
life resulting from changes in clinical outcome 
suggested the potential for ECMO treatment to 
have an important economic impact in the NHS. 
Full economic evaluation was therefore built into 
the CESAR trial. The economic data collection and 
economic analysis took the perspectives of the NHS 
and of the household.
Data about resource use and economic outcomes 
[quality-adjusted life-years (QALYs)], were collected 
from participating patients. Estimated QALYs 
were based on EuroQol 5 dimensions (EQ-5D) 
responses at 6 months and were weighted using 
UK population values for health states. Studies of 
the key cost-generating events were undertaken, 
and analyses of cost–utility at 6 months post 
randomisation and modelled lifetime cost–utility 
were performed.DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
xi
Lifetime QALYs were estimated based on the 
assumption that the quality of life of all surviving 
patients improved up to 24 months from 
randomisation, and that at 24 months their health 
states were the same as those of other adults of 
similar age and gender in the UK population. It 
was also assumed that all survivors had the same 
average life expectancy as adults of similar age and 
gender in the UK population. This assumption was 
based on our experience of long-term follow-up 
of patients who had been previously treated with 
ECMO.
Patients allocated to ECMO incurred average 
total costs of £73,979 compared with £33,435 
for those undergoing CM (UK prices, 2005). At 
6 months post randomisation, the additional 
cost of a survivor without severe disability of 
ECMO compared with CM was £251,360. ECMO 
treatment resulted in 0.03 predicted additional 
QALYs at 6 months’ follow-up. A lifetime model 
predicted the cost per QALY of ECMO to be 
£19,252 (95% CI £7622 to £59,200) at a discount 
rate of 3.5%. Lifetime QALYs gained were 10.75 
for the ECMO group compared with 7.31 for the 
conventional group.
Costs to patients and their relatives, including out 
of pocket and time costs, were higher for patients 
allocated to ECMO.
Conclusions
A major limitation of this study is the lack of 
standardisation of care in the conventional arm. 
This was because it was not possible for the 
conventional intensive care providers to reach a 
consensus as to what constituted optimal care. 
An alternative strategy of transferring all the 
patients to Glenfield to be cared for by the ECMO 
team was dismissed by collaborators as they did 
not consider the ECMO team to be sufficiently 
expert in the provision of conventional intensive 
care. The other possibility considered was to use 
a single centre to provide all of the conventional 
care, but this was impossible as such a centre 
does not exist in the UK. The trial team therefore 
took the pragmatic decision to recommend what 
was proven to be the best ventilation strategy 
(the low volume ARDSNet protocol) but allow 
individual intensivists to determine what they 
thought was the best treatment for their patients. 
If this decision had not been taken then it would 
not have been possible to conduct the study. 
This pragmatic design meant that CESAR was 
comparing treatment in an expert centre where 
ECMO was part of the treatment algorithm with 
the treatment available to the general public in the 
UK as a whole. Compared with CM, transferring 
adult patients with severe but potentially reversible 
respiratory failure to a single centre specialising 
in the treatment of severe respiratory failure for 
consideration of ECMO significantly increased 
survival without severe disability. Use of ECMO in 
this way is likely to be cost-effective when compared 
with other technologies currently competing for 
health resources.
Trial registration
This trial is registered as ISRCTN47279827.DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
1
Chapter 1  
Introduction
T
he mortality rate for adults with severe 
respiratory failure is very high and has 
improved only marginally in the majority of centres 
over the last 20 years.1,2 As there may be as many 
as 350 adult patients with severe, but potentially 
reversible, respiratory failure in the UK each year, 
this is a significant problem. Current management 
uses intermittent positive pressure ventilation 
(IPPV). The airway pressures and oxygen 
concentrations required to maintain adequate 
blood gases are often very high in patients with 
severe respiratory failure, and this combination of 
barotrauma, volutrauma and oxygen toxicity can 
prevent lung recovery. The only type of ventilation 
that has been proven in a randomised controlled 
trial (RCT) to improve outcome in adults with 
moderate, but potentially reversible, respiratory 
failure is the use of gentle lung protective 
ventilation.4 Unfortunately patients with severe, but 
potentially reversible, respiratory failure have such 
bad lung disease that they are unable to maintain 
homeostasis if such lung protective ventilation is 
used. Ironically, these are the very patients who 
need lung protective ventilation the most. An 
alternative treatment, extracorporeal membrane 
oxygenation (ECMO), uses cardiopulmonary 
bypass technology to temporarily provide gas 
exchange to patients with severe, but potentially 
reversible, respiratory failure. During ECMO, 
ventilator settings can be reduced, and ‘lung rest’ 
achieved, thereby allowing the lungs to recover. 
There is currently no good evidence from RCTs to 
compare ECMO with conventional management 
(CM) for important clinical outcomes.
Patients are usually considered for ECMO when 
they have such severe disease that they continue 
to deteriorate despite maximal optimum 
‘conventional’ treatment. For the purposes of 
this discussion, ‘conventional’ will be defined as 
any treatment that relies on the patient’s lungs to 
provide gas exchange. Conventional treatment 
therefore includes ventilation with inhaled nitric 
oxide, prone ventilation4–6 and high frequency 
oscillation,7 as well as the more usual types of 
positive pressure ventilation. ECMO has been 
proven to increase survival in neonatal patients 
with severe respiratory failure in a rigorous RCT.8,9 
This UK collaborative neonatal ECMO RCT 
convincingly demonstrated the effectiveness of 
ECMO in improving patient survival without severe 
disability. Neonatal ECMO in the UK is now a 
supra-regional service receiving central funding. 
The use of ECMO as it is currently practised in 
older children10 and adults11 is more controversial, 
and has yet to be evaluated in an RCT in the UK.
Previous studies
A review of the literature was carried out to identify 
all studies relevant to adult ECMO. MEDLINE was 
searched using ‘adult’, extracorporeal life support 
(ECLS) and ‘ECMO’ as keywords. In addition 
the investigators are closely aware of the ECMO 
literature, as they are leading members of the 
international ECMO community. Only two RCTs 
have been reported,1,12 both from the USA, but they 
used such different approaches that they have not 
been combined as a formal meta-analysis. Neither 
of these studies investigated high flow venovenous 
(VV) ECMO, which is the current technique of 
choice for adult respiratory failure. Each study 
is detailed below, followed by the recent non-
experimental evidence.
The first study was an RCT of adult ECMO, 
conducted by the US National Institutes of 
Health (NIH),1 in the early days of extracorporeal 
support in the 1970s. Survival in both groups was 
very poor (around 10%), and no difference was 
shown in survival between the conventional and 
ECMO treated groups. Only very small numbers 
of patients were treated in each centre (fewer 
than five). There were a number of important 
differences in the perfusion and ventilation 
techniques used during this trial compared 
with those used today. Firstly, veno-arterial (VA) 
rather than VV perfusion was used, and this was 
thought to be responsible for the high incidence 
of pulmonary micro-thrombosis and fibrosis 
seen in the lungs of the ECMO patients (due 
to reduced pulmonary blood flow). Secondly, 
patients were anticoagulated to such a degree 
that severe bleeding occurred. Thirdly, high 
pressure ventilation was continued during ECMO, Introduction
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resulting in continued ventilator lung injury with 
barotrauma and volutrauma.13,14 Finally, the mean 
duration of ventilation prior to ECMO in the NIH 
ECMO trial was more than 9 days, whereas it is now 
well recognised that after 7 days of high pressure 
ventilation with high fraction of inspired oxygen 
(FiO2), the lungs have limited powers of recovery.15
The second RCT was more recent, and concerned 
the related technique of extracorporeal carbon 
dioxide removal (ECCO2R).12 This showed no 
difference between ECCO2R and conventional 
treatment. Again there were numerous differences 
in the clinical and perfusion protocols between this 
trial and those in widespread use in the majority 
of centres currently.16,17 Firstly, the experimental 
arm of the trial used low flow ECCO2R in a group 
of patients who had severe lung disease, which 
warranted higher flow ECMO with full support of 
oxygenation and carbon dioxide removal. This was 
demonstrated by the need to increase the airway 
pressure in the ECCO2R group halfway through 
the study. The reliance on the patient’s lungs to 
provide oxygenation, especially at such high airway 
pressures, also eliminated any possibility of lung 
rest. Also, despite the involvement of one of the 
team in the 1970s NIH ECMO trial, the ECCO2R 
programme in this trial was not well developed 
prior to the study (as the team had only provided 
ECCO2R to sheep and one patient before starting 
the trial). The high incidence of bleeding and 
thrombotic complications reported in this study 
may attest to this inexperience. In addition, the 
conventional treatment used in the trial was 
pressure controlled inverse ratio ventilation 
(PCIRV) using a computer-controlled algorithm. 
The results of this treatment showed a 44% survival 
rate compared with expected survival rates of 
less than 20% in other similar series of patients.2 
Despite this, the survival rate in the ECCO2R group 
was the same as in the ‘conventional’ group. The 
success of the PCIRV protocol in this study has 
led to the wide adoption of the technique within 
‘conventional’ ventilatory management with a 
survival rate of 66% for patients with moderate to 
severe respiratory failure [mean Murray lung injury 
score 2.8, mean ratio between the oxygen tension 
in the arterial blood and the fraction of inspired 
oxygen (PaO2/FiO2) 88 mmHg].18 Unfortunately 
no other authors have been able to duplicate the 
PCIRV results of Morris et al.12 for patients with 
severe progressive respiratory failure.
Because the two trials described above have little 
relevance to the high flow VV ECMO regimens 
used in the majority of centres worldwide, the only 
relevant evidence consists of observational studies. 
By the nature of their design, the information they 
provide is potentially biased, and must therefore be 
viewed with caution.
Recent case series of patients with similar degrees 
of respiratory failure to the eligibility criteria 
for the second trial suggest survival rates with 
conventional ventilation of 33–44%19,20 compared 
with rates of up to 66% with high flow ECMO 
(including full support of oxygenation and lung 
rest), provided by experienced teams principally in 
the USA, UK and Germany.11,15–17
In a cohort study of the first 50 adult patients to 
receive ECMO for respiratory support at Glenfield 
Hospital, Leicester, UK, patients had severe 
respiratory failure as shown by the mean pre-
ECMO Murray score of 3.4 [standard deviation 
(SD) 0.5] and PaO2/FiO2 ratio of 65 mmHg 
(SD 36.9). They were referred for ECMO with 
severe respiratory failure caused by either the 
acute respiratory distress syndrome (ARDS) or 
pneumonia. The overall survival rate was 66%.11
For the reasons outlined above, it was impossible 
to reach firm conclusions from the above 
experimental and observational data regarding 
the clinical effectiveness or cost-effectiveness of VV 
high flow ECMO for respiratory failure in adults 
without an RCT.
ECMO received a Cii categorisation (safety and/
or efficacy not yet fully established; procedure 
requires a fully controlled evaluation) from the 
UK Safety and Efficacy Register of the New 
Interventional Procedures of the Medical Royal 
Colleges (SERNIP). During the study SERNIP was 
superseded by the National Institute for Clinical 
Excellence (NICE; now known as the National 
Institute for Health and Clinical Excellence) which 
issued the following guidance in January 2004: 
‘ECMO in adults is under evaluation in the Health 
Technology Assessment Programme’s CESAR 
(Conventional Ventilation or Extracorporeal 
Membrane Oxygenation for Severe Adult 
Respiratory Failure) trial. Clinicians wishing to 
undertake this procedure are strongly advised to 
enter eligible patients into this trial.’
Economics of ECMO
Given the high cost of treatment, ECMO is 
considered an expensive technology for many 
funding systems. However, conventional treatment DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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for severe respiratory failure is also one of the 
more costly forms of care in any health system.21 
Differences in lengths of stay and types of care 
received by patients following either clinical 
pathway may result in different statistical 
distributions of cost for inpatient care. Also, 
because appropriate care is provided in relatively 
few centres, the location of care and need for 
specialist transport for patients also affects the costs 
of care. Moreover, if there is increased survival to 
discharge from hospital, then there will be more 
use of services in primary and community care, 
and requirement for help for people recovering 
at home. Thus the health service costs and the 
household costs might fall at any stage of the 
treatment and recovery, and in many different 
forms. In addition to the costs of alternative forms 
of care, the economic choice depends on the value 
of the outcome gained.
Previous economic evaluations
A literature search failed to find any economic 
evaluation studies of adult ECMO. However, 
there has been a series of economic evaluations of 
ECMO in babies alongside the UK collaborative 
randomised trial of neonatal ECMO,22 which 
reported the estimated additional cost (UK 1994–5 
price) of ECMO per additional surviving infant 
with no disability as £75,327 at 1 year of age. 
Follow-up at 4 and 7 years for the same study shows 
the incremental cost (UK 2001 and 2003 prices) 
of neonatal ECMO to be £24,775 and £23,566 
per disability-free life-year gained respectively.23,24 
Similarly, a retrospective cost–utility analysis of 
ECMO in children25 reports costs of US $24,386 
per quality-adjusted life-year (QALY) saved for 
‘salvage ECMO’. In all cases, in spite of the high 
cost of ECMO, the incremental cost per QALY was 
within health-care funders’ range of acceptable 
value for money.
For the reasons outlined above, it is impossible 
to reach firm conclusions from the above 
experimental and observational data regarding 
the clinical effectiveness or cost-effectiveness of VV 
high flow ECMO for respiratory failure in adults. 
The aim of the CESAR (Conventional ventilation 
or ECMO for Severe Adult Respiratory failure) 
trial was therefore to assess whether for patients 
with severe, but potentially reversible, respiratory 
failure, ECMO would increase the rate of survival 
without severe disability by 6 months post 
randomisation and would be cost-effective from the 
viewpoints of the UK NHS and society, compared 
with conventional ventilatory support.DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 2  
Methods
C
ESAR was a ‘pragmatic’ RCT, similar to the 
UK neonatal ECMO RCT,8,9 mirroring usual 
practice in the UK. For patients with severe, 
but potentially reversible, respiratory failure, 
the primary hypotheses were that ECMO would 
increase survival without severe disability by 
6 months post randomisation compared with 
conventional ventilation, and be cost-effective 
from the viewpoints of the NHS and society. Severe 
disability was defined as being unable to wash or 
dress oneself and being confined to bed.
The clinical and economic protocols have 
been published previously and can be found in 
Appendices 3 and 4.
Three types of centre were included: (1) the 
ECMO centre at Glenfield Hospital, Leicester; 
(2) conventional treatment centres (CTCs); and 
(3) referring hospitals (RHs). Intensive care units 
(ICUs) in the UK were beginning to be formed 
into collaborative local critical care networks as 
the CESAR trial started. Where networks had been 
established, CTCs were defined as those centres 
acknowledged by the network leads to provide an 
appropriately high standard of conventional care. 
In the absence of this classification, the criteria for 
admission of more than 350 patients per year and 
provision of pressure controlled ventilation and VV 
haemofiltration were used as markers of sufficiently 
large units. RHs were non-CTCs that could enter 
patients into the trial, if they were prepared to 
transfer the patient to a CTC should the allocation 
be to CM. It is not standard practice in the UK to 
transfer patients between ICUs for treatment of 
respiratory failure.
One hundred and three hospitals obtained ethics 
committee approval to collaborate in the study, of 
which 92 were CTCs and 11 were RHs.
Patients could be entered into the trial if aged 
18–65 years with severe but potentially reversible 
respiratory failure, defined as a Murray score 
(using all four parameters and FiO2 = 1)26 
≥ 3.0, or uncompensated hypercapnoea with a 
pH < 7.20 despite optimal conventional treatment. 
Reversibility was based on the clinical opinion of 
one of three duty ECMO consultants (RK Firmin, 
GJ Peek and AW Sosnowski). The criteria for 
case selection have been previously discussed.27 
Trial registration could also be discussed when 
the Murray score was ≥ 2.5. If the patient then 
continued to deteriorate, this prior discussion 
could expedite trial entry.
Patients were excluded if they had been on high 
pressure (peak inspiratory pressure > 30 cmH2O) 
and/or high FiO2 (> 0.8) ventilation for more 
than 7 days (168 hours); had signs of intracranial 
bleeding; had any other contraindication to limited 
heparinisation; or had any contraindication to 
continuation of active treatment. Ventilation 
parameters were assessed on an hourly basis: a 
patient would count as having had an hour of high 
pressure or high FiO2 ventilation if they had either 
a peak airway pressure above 30 cmH2O or an FiO2 
above 0.8.
Allocation of patients
The referring intensivist contacted the advisory 
team at Glenfield to confirm eligibility and bed 
availability. He or she then discussed the trial with 
the patient’s relative(s), gave written information 
(see Appendices 1 and 2), and asked for agreement 
to trial entry and obtained assent from the next of 
kin (once patients had recovered sufficiently they 
were told that they had been entered into a clinical 
trial and were given the opportunity to withdraw; 
three patients in the conventional arm declined 
further involvement in the study at this point). 
The advisor then telephoned the independent 
central randomisation service (see Appendix 2). 
Randomisation was to CM or to consideration of 
ECMO.
To ensure close balance between treatment 
groups for several patient factors, a dynamic 
process (minimisation) was used, which took into 
account the characteristics of the patients already 
entered into the trial. After the first patient was 
allocated treatment using simple randomisation, 
the next patient to enter the trial was allocated to 
whichever treatment group improved the overall Methods
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balance according to a pre-selected set of baseline 
minimisation criteria, namely type of centre (CTC 
or RH); age (18–30, 31–45, 46–65 years); hours 
of high pressure and/or high FiO2 ventilation 
(0–48, 49–168); mode of trial entry (i.e. hypoxic/
hypercarbic); diagnostic group (pneumonia, 
obstetric ARDS, trauma including surgery within 
previous 24 hours, other ARDS, and other); and 
numbers of organs failed (one or two, or three or 
more) where organ failure was a Sepsis-related 
Organ Failure Assessment (SOFA) score for that 
organ of ≥ 2.28,29 After 40% of recruitment had been 
completed, an additional step was incorporated 
such that if four successive randomisations for 
the same centre had the same allocation, the next 
allocation was to the other treatment. To protect 
allocation concealment, this amendment was not 
revealed to the participating centres.
Emergency Inclusion Protocol
During the trial, ECMO was not available to 
eligible patients outside the study. If a hospital 
from outside the study wished to refer a patient, 
the ECMO transport team went to the hospital to 
assess the patient and, if appropriate and assent 
was obtained, to assume responsibility for the 
clinical care. The patient was then randomised. If 
the patient drew CM, the ECMO team transported 
the patient to the nearest available CTC, and 
if randomised for ECMO, they transported the 
patient to Glenfield.
Interventions
Conventional management
This was the intensive care provided as standard 
at each CTC. This could include any treatment 
prescribed by the intensivist (excluding 
extracorporeal gas exchange). A low volume 
ventilation strategy was recommended, i.e. tidal 
volume 4–8 ml/kg of body weight.3 We defined 
adherence as a plateau pressure < 30 cmH2O (or 
if plateau pressure was not measured, the peak 
inspiratory pressure). Patients could not be ‘crossed 
over’ to receive ECMO.
ECMO
Patients randomised to ECMO were transferred to 
Glenfield for consideration of ECMO. Treatment 
was according to published institutional protocols. 
Patients who could be stabilised on lung protective 
ventilation were treated without ECMO (see below). 
Patients who were unstable or who required high 
pressure/high FiO2 ventilation received VV ECMO 
via percutaneous cannulation. The ECMO circuit 
used bladder-box servo-regulation, Stockert 
Roller® pumps (Stockert, Freiburg, Germany) with 
Tygon S-65-HL® (Norton Performance Plastics, St 
Gobain, Akron, Ohio, USA) raceway tubing and 
one or two (depending on body weight) Medos 
Hi-Lite 7000® membrane oxygenators (Medos, 
Stollberg, Germany) with 100% O2 as the sweep 
gas. Partial anticoagulation was maintained with 
heparin titrated to give an activated clotting time 
(Actalyte, Max-ACT; Helena, Beaumont, Texas, 
USA) of 140–200 seconds. On ECMO, lung rest 
was achieved by reducing ventilation to peak 
inspiratory pressure (PIP) of 20–25 cmH2O, positive 
end-expiratory pressure (PEEP) of 10–15 cmH2O, 
rate of 10, duration of inspiration to duration of 
expiration (I:E) ratio of 1:1, and FiO2 of 30% in 
pressure control mode using Siemens Servo 300® 
ventilators (Siemens, Solna, Sweden). Patients 
were fed appropriately and diuresed to dry weight. 
Haemoglobin was maintained at 14 g/dl. Steroids 
were given to patients with severe sepsis who had 
a random cortisol concentration of ≤ 414 nmol/l30 
and also to patients who had non-recovery of lung 
function. Patients were weaned from ECMO and 
decannulated when chest radiograph appearance 
and lung compliance improved and adequate 
gas exchange without excessive ventilation had 
returned: in general this meant a peak airway 
pressure < 30 cmH2O and an FiO2 < 0.6, to give an 
arterial carbon dioxide pressure (PaCO2) < 6 KPa 
and a PaO2 > 10 KPa. Patients who did not receive 
ECMO could be managed with ventilator settings 
given above. These were usually patients who were 
volume overloaded and responded to diuresis 
with a rapid diminution in airway pressure and 
FiO2. Patients developing liver failure (bilirubin 
> 200 µmol/l) were supported with MARS® 
(Molecular Adsorbents Recirculating System, 
Gambro AB, Stockholm, Sweden).31 The full 
Glenfield Hospital ECMO programme treatment 
protocol can be found in Appendix 5.
The ECMO circuit was constantly managed by 
a trained ECMO specialist nurse, in addition to 
the patient’s intensive care nurse. If the patient’s 
condition altered such that ECMO was no longer 
appropriate, it was not used.
Transport
All inward transport was provided by the ECMO 
team. If the team decided that it was not safe to 
move the patient, then he or she remained in 
the original unit until considered safe to transfer, 
recovered or died.DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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Outcome measures
The primary outcome measure was death or 
severe disability at 6 months [defined as death 
by 6 months or before discharge from hospital at 
any time to end of data collection, or where the 
answer to the first two questions of the EuroQol 5 
dimensions questionnaire (EQ-5D) were ‘confined 
to bed’ and ‘unable to wash or dress yourself ’, i.e. 
the worst possible scores for the domains for self-
care and for mobility].
The secondary outcomes included a range of 
hospital indices: duration of ventilation, use of 
high frequency/oscillation/jet ventilation, use of 
nitric oxide, prone positioning, use of steroids, 
length of ICU stay, and length of hospital stay 
– and (for ECMO patients only) mode (VV/VA), 
duration of ECMO, blood flow and sweep flow.
Death of patients in the trial was recorded during 
the period of follow-up whenever it occurred. 
Staff at the CESAR trial data management centre 
maintained contact with all centres that had 
patients being treated within the CESAR trial, thus 
ensuring complete reporting.
In addition, health status at 6 months after 
randomisation was assessed in terms of activities of 
daily living, quality of life, respiratory symptoms, 
cognitive psychological state and lung function.
Six-month follow-up
This was performed by trained researchers blinded 
to the random allocation in the patients’ homes. 
Patients and their relatives were instructed not to 
reveal which treatment was used (see Appendices 1 
and 2). A special scarf covered the neck, masking 
cannulation status. The assessment included SF-36 
[Short Form (36 items) health survey],32 EQ-5D,33 
St George’s Hospital Respiratory Questionnaire,34 
Hospital Anxiety and Depression Scale35 and Mini-
Mental State Examination,36 as well as specific 
sleep questions from the functional limitation 
profile.37 Where applicable, effects on the carer 
were measured using the carer strain index.38 
Lung function was assessed by spirometry. Upper 
arm movements were assessed, as restriction 
of these has been previously noted in patients 
following ECMO.39 If a patient was still in hospital, 
a modified assessment was carried out there. If a 
home visit was unacceptable, patients were offered 
a telephone interview or postal questionnaire. 
For those refusing this, permission was requested 
for information to be sought from their general 
practitioner.
Sample size
Seventy per cent mortality in the control group 
was anticipated when carrying out the initial 
power calculations in 1998/9, based on patients 
with similar PaO2/FiO2 ratio in the NIH ARDS 
network database (RH Bartlett, University of 
Michigan, USA, 1999, personal communication), 
confirmed by the Case Mix Programme (Intensive 
Care National Audit & Research Centre, ICNARC) 
database, in which the mortality of the 1506 
patients whose PaO2/FiO2 ratio was ≤ 100 mmHg 
was 61.6%. The mean PaO2/FiO2 ratio of the 
ECMO patients11 was 65 mmHg (SD 37 mmHg). 
Assuming a 10% risk of severe disability among 
survivors in both arms, alpha = 0.05 (two-sided 
test) and beta = 0.2, 120 patients would be 
required in each group (i.e. 240 in total) to detect 
a reduction in the rate of primary outcome by a 
quarter from 73% to 55%, a conservative estimate 
based on the descriptive studies of adult ECMO 
already discussed. A number of other scenarios 
were shown on a sample size grid in the published 
clinical protocol39 (see Appendix 3). For example, 
the same size sample could detect a reduction 
by a third if the primary outcome rate in the 
control group was about 57%. The sample size was 
reviewed in June 2003 by the independent Data 
Monitoring Committee (DMC) when recruitment 
was running at less than 60% of its target. As the 
primary outcome rate in the control group was 
then 67%, it was agreed that a lower sample size 
(180 patients) would be sufficient to allow detection 
of reduction by a third and the HTA programme 
agreed an extension of the funding period to allow 
recruitment of 180 patients.
Statistical analysis
Primary analyses were by intention to treat. 
Secondary analyses included subgroup analyses, 
based on the minimisation criteria at trial entry, 
and a per protocol analysis. The DMC reviewed 
interim analyses in strict confidence on seven 
occasions. They were charged with informing the 
Trial Steering Committee if there was proof beyond 
reasonable doubt (based on the Peto–Haybittle 
stopping guidelines)40,41 that the data indicated that 
any part of the protocol under investigation was 
either clearly indicated or contraindicated (either 
for all patients or for a particular subgroup), or Methods
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it was evident that no clear outcome would be 
obtained with the current trial design. Except for 
those who supplied the confidential information, 
everyone (including the Trial Steering Committee, 
funders, collaborators and administrative staff) 
remained ignorant of the results of the interim 
analysis.
Ethical considerations
The trial was approved by the Trent Multicentre 
Research Ethics Committee (MREC) as well 
as relevant Local Research Ethics Committees 
(LRECs).
Economics methods
Design of the economic 
evaluation alongside the CESAR 
trial
The primary objective of the economic evaluation 
was to assess incremental cost-effectiveness of 
ECMO, in terms of the incremental costs of 
additional survival with and without disability at 
6 months post randomisation, compared with 
conventional treatment for severe respiratory 
failure. The evaluation set out to assess the cost 
of treatment to the health and social services and 
to patients and their families in each treatment 
group. The design of the economic evaluation 
was based on published recommendations for 
best practice.42 These involve defining: the type 
of economic evaluation to be conducted; the 
comparator form of care; the perspective of the 
study and time horizon for costs and outcomes; 
appropriate outcome measures for each perspective 
and type of evaluation; identification, measurement 
and valuation of resources; estimation of unit 
costs; and a plan for economic analysis, which 
includes decisions on discounting future costs and 
consequences, tackling uncertainties and, finally, 
the presentation of results.
The objectives of the economic evaluation were:
1.  To compare the costs of a policy of referral for 
ECMO with those of conventional treatment.
2.  To assess the cost-effectiveness of referral for 
ECMO compared with conventional treatment 
in terms of additional survival with and without 
disability at 6 months post randomisation.
3.  To assess the cost–utility of referral for ECMO 
compared with conventional treatment in 
terms of utility gain as measured by EQ-5D at 
6 months’ follow-up.
4.  To assess the cost–utility of referral for ECMO 
compared with conventional treatment in terms 
of utility gain as measured by EQ-5D, and 
other sources, over a predicted lifetime.
Type of economic evaluation
The first two analyses were planned to cover only 
the 6-month period from randomisation for which 
the CESAR trial collected data from patients. 
The first planned analysis was a cost-effectiveness 
analysis with increase in survival without severe 
disability at 6 months (the primary outcome in 
the CESAR trial) as the main outcome measure. 
A short-term cost–utility analysis was planned, in 
which health benefits would be quantified in terms 
of QALYs measured using the instrument EQ-
5D at 6 months. Lifetime cost–utility analysis was 
modelled using a decision model based on CESAR 
trial results and including additional data for 
predicted lifetime QALYs and health-care costs.
Comparator
The ideal comparator for any economic evaluation 
designed to assess the cost-effectiveness in a 
particular context is the most commonly used 
treatment for the condition in that context. 
The CESAR trial was designed as a pragmatic 
comparison, in which patients allocated to 
conventional care were receiving treatment that 
would be the normal form of care in the NHS. 
To ensure that the patients in the control group 
received as near as possible the best practice of 
care, the CESAR trial protocol specified aspects 
of service provision that had to be considered, 
including facilities available at the participating 
ICUs, experience of treating such patients, and 
certain aspects of the clinical treatment protocol 
for ventilated patients.39 In general, however, 
the comparator group was intended to be 
representative of NHS care provision (in qualifying 
ICUs) for severe but potentially reversible 
respiratory failure during the period of the trial.
Perspective or viewpoint for 
analyses
In the UK, NICE proposes that applicants 
presenting economic analyses for NICE appraisals 
should adopt an NHS perspective.43 However, 
there are aspects of public patient choice and 
valuation that may not be considered in such an 
analysis. Economic evaluators are guided to take 
a societal viewpoint if possible.42 As the ECMO 
technology may be adopted for review by NICE 
or a similar agency in the UK, it was decided that DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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the perspective for the CESAR trial should include 
both the NHS and societal perspectives. The 
latter viewpoint is important, as the results of this 
study are likely to have economic impacts other 
than through health-care requirements if there 
is significantly increased survival of either able-
bodied or disabled adults. It was also anticipated 
that the results of the trial may provide useful 
information for a wider international audience 
where different ranges of services are provided 
within the health system.
Time horizon for economic 
evaluation
The duration of follow-up in the CESAR trial was 
6 months. This did not allow the full long-term cost 
and benefits to be measured. However, it satisfied 
the recommendation of the American Thoracic 
Society for cost-effectiveness analyses of ICU 
therapies to have a minimum follow-up period of 
6 months.21 However, to meet our fourth objective, 
prediction and modelling of long-term (lifetime) 
costs and benefits were also undertaken.
Outcome measures for 
economic evaluation
Survival without severe disability
The cost-effectiveness analysis focused on the 
primary outcome measure for the CESAR trial.
Quality-adjusted life-years
The calculation of QALYs was based on assessment 
of health-related quality of life at 6 months from 
randomisation. The EQ-5D is a standardised 
instrument used for measuring health outcomes. 
The part of the EQ-5D questionnaire used to 
elicit health status comprises five questions, 
each of which has three alternative response 
categories. The five items assess mobility, self-
care, usual activity, pain/discomfort and anxiety/
depression. These items can be used by themselves 
as descriptions of respondents’ health states. 
Responses were also scored by means of weights 
obtained from the valuations that other samples 
from the general population have assigned to 
health states using visual analogue scales. Quality-
adjusted health utility weights for each patient 
were calculated for the CESAR trial using UK 
specific utility values for each patient’s response 
to the EQ-5D at 6 months. QALYs gained at 
6 months were estimated assuming that the value 
of the health state at trial entry was zero and that, 
over the months of survival, patients experienced 
linearly increasing quality of life up to the level at 
6 months.
Estimates of lifetime QALYs were predicted based 
on assumptions of gradual improvement of quality 
of life up to 2 years from randomisation, and of 
predicted life expectancy based on age specific 
rates for the population of England and Wales. 
Age and sex specific life expectancy was calculated 
for each surviving patient in the trial using UK life 
tables.44 It was assumed that, at 24 months post 
randomisation, all surviving trial patients attained 
the same average life expectancy and health state 
as adults of similar age in the UK population.45–49 It 
was assumed that average health states for different 
age groups would be the same as those obtained 
from the 1996 Health Survey for England.50 This 
assumption was based on our experience of long-
term follow-up of patients who had been previously 
treated with ECMO.
Cost estimation
Identifying resource use
For the CESAR trial, relevant aspects of resource 
use were identified using expert advice (managers 
and medical, nursing and patient representatives 
all commented on the draft lists) and considering 
the items included in the economic evaluation 
of neonatal ECMO.22 A list of resource items 
important from one or more viewpoints is given in 
Table 1.
This includes resource use associated with initial 
stay in intensive and high-dependency care units 
at different levels of care (measured by number of 
organs supported – see below), use of ambulance 
transport, stays in other hospital wards before 
discharge, costs of visiting incurred by relatives 
whilst patients are in hospital, resource use after 
discharge up to 6 months, major changes in 
household, out of pocket expenses of patient and 
family, loss of paid and unpaid working time, 
changes in working time, and informal care.
Measuring resource use
In the CESAR trial, resource use data were 
collected prospectively for every trial participant 
at various points of his or her progress, from 
recruitment to the trial until follow-up, using a 
series of data forms and questionnaires. Some, but 
not all, of these were additional to the instruments 
used for the CESAR trial management and clinical 
outcome data collection.39 These instruments are:
(a)  Daily organ support form – completed by 
critical care unit staff for each trial participant 
on a daily basis, and used to classify intensity Methods
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TABLE 1  Items of resource use and sources for unit costs in the CESAR trial
Resource items Source  References to sources
From trial entry to discharge from hospital
Days of organ support ICU costing study Hibbert et al. 200551
Days on ECMO ICU costing study  Hibbert et al. 200551
Days on conventional ventilation ICU costing study  Hibbert et al. 200551
Days in intensive care ICU costing study  Hibbert et al. 200551
Days of other hospital stay before 
discharge
PSSRU (www.pssru.ac.uk/uc/uc2005contents.
htm)
Curtis and Netten 200552
Miles transported by air ambulance Cost provided by transport provider
Miles transported by land ambulance Cost provided by ambulance trusts
From discharge to follow-up at 6 months
Telephone contacts with GP PSSRU Curtis and Netten 200552
Contacts with NHS Direct NHS Direct (2005 personal communication)
Visits to GP PSSRU Curtis and Netten 200552
Home visits by nurse PSSRU Curtis and Netten 200552
Visits to counsellor PSSRU Curtis and Netten 200552
Visits to physiotherapist PSSRU Curtis and Netten 200552
Visits to occupational therapist PSSRU Curtis and Netten 200552
Visits by health visitor PSSRU Curtis and Netten 200552
Days of inpatient stay PSSRU Curtis and Netten 200552
Outpatient visits PSSRU Curtis and Netten 200552
A&E visits PSSRU Curtis and Netten 200552
Visits to day hospital/day care PSSRU Curtis and Netten 200552
Days in residential care PSSRU Curtis and Netten 200552
Days in nursing home PSSRU Curtis and Netten 200552
Medication PSSRU Curtis and Netten 200552
Visits by social worker PSSRU Curtis and Netten 200552
Visits by home care worker PSSRU Curtis and Netten 200552
Aids and adaptations Reported by participants and some estimated 
from personal enquiries by researcher to 
equipment suppliers
Value of hours of informal care Office of National Statistics Office of National Statistics 
200353
Miles of private car use for health care Automobile Association Automobile Association 200754
Out of pocket expenses Reported by CESAR trial patients
Major changes in household Reported by CESAR trial patients
Child-care costs Reported by CESAR trial patients
Change in employment Reported by CESAR trial patients
Change in benefits or allowances Reported by CESAR trial patients
Loss of income from employment Reported by CESAR trial patients
Other costs Reported by CESAR trial patients
Other changes Reported by CESAR trial patients
A&E, accident and emergency department; PSSRU, Personal Social Services Research Unit.DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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of resources used during the intensive care 
ECMO/conventional treatment period.
(b)  Transport form (a) at trial entry – completed 
by Glenfield Hospital transport team to record 
transfer of trial participants to ECMO centre or 
conventional treatment centres.
(c)  Transport form (b) – completed by Glenfield 
transport team to record ambulance journey 
of participants returning either to the original 
recruiting hospital or another ICU after 
ECMO.
(d)  Outcomes data sheet – completed by medical 
staff, and records date on death of patient (if 
applicable), date of discharge, date of transfer 
to another hospital/home, use of ambulance for 
transfer, etc.
(e)  Events diary – to be completed and kept by all 
participants to document all services used from 
discharge to follow-up as an aide memoire to 
help them to answer questions at 6 months. 
This included information about informal help 
received as well as formal services.
(f)  Patient cost questionnaire at 6-month follow-
up – administered by trained interviewer at 
patient’s home or by telephone to collect 
resource use data from discharge to follow-up, 
covering items recorded in (e) above.
(g)  GP proforma – completed by GPs to collect 
medication use of those patients who refused 
the 6-month follow-up but gave permission for 
use of GP records.
Items (a)–(g) above are reproduced in Appendix 2.
The events diary (e) and the patient cost 
questionnaire (f) were piloted with five patients 
discharged from Glenfield Hospital ICU, and the 
GP proforma (g) was piloted with five general 
practitioners. Interviewers were trained in the 
administration of the patient cost questionnaire 
(f). As it was anticipated that many ambulance 
trusts across the UK might become involved in 
transporting trial patients, all ambulance trusts 
were contacted and agreement obtained to provide 
costs of patient journeys (including overhead and 
running costs) as and when they took place during 
the trial.
Two items of resource use not collected alongside 
the trial were resource use associated with and 
following a patient’s death in the critical care 
unit, and costs incurred by relatives whilst visiting 
patients in intensive care or during a hospital 
stay. These items were excluded from the data 
collection from CESAR trial patients because of the 
practical difficulty of collecting data and because a 
well-defined methodology was not available at the 
early stages of planning the CESAR trial. However, 
the cost of visiting patients in intensive care was 
thought likely to be an important social cost, and 
is being estimated by a separate study in a sample 
of CESAR centres and is described in more detail 
below (see Estimating unit costs).
Resource data collection for the 
economic evaluation
Following recruitment, the progress of all 
participants was tracked initially until their 
discharge from hospital so that resource use could 
be accurately measured and collected at each stage. 
During the intensive treatment period (ECMO or 
conventional ventilation) data were collected on 
the number of days spent in each treatment mode, 
including daily information on the number of 
organs supported and the level of critical care (ICU 
or high dependency unit). After transfer to another 
hospital or another ward within the same hospital 
following the acute phase of the illness, resource 
use was measured as number of inpatient days up 
to discharge.
Details of all ambulance use related to transferring 
trial patients at recruitment were collected by the 
Glenfield transport team, and details of all other 
ambulance journeys (for example transfer between 
hospitals) were collected by the relevant hospitals 
and sent to the research team. Data collected 
included date, time, origin and destination of 
journey, mode of transport (road ambulance, fixed 
wing aircraft or helicopter), duration of journey, 
and distance travelled by the patient.
After discharge from hospital, each participant was 
sent details of the forthcoming interview and the 
‘events diary’ to record resource use. The patient 
was asked to give permission for one of a series of 
options to take place 6 months after trial entry: (1) 
face-to-face interview, (2) telephone interview, (3) 
postal questionnaire and (4) collection of resource 
use from GP records. Those patients who were 
still in hospital at 6 months, if fit enough, were 
asked to give permission to be interviewed at their 
hospital bedside using a very short resource use 
questionnaire.
Estimating unit costs
In order to estimate the total cost of treatment 
for each trial participant, the respective 
quantities of resource use were multiplied by their 
corresponding unit costs. Some resources used 
by participants are in the form of actual costs Methods
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(not charges) and do not need any valuation. 
For example, costs of ambulance journeys were 
obtained directly from the relevant ambulance 
service providers and incorporated all overhead 
and running costs. The unit costs of most items 
of resource use were obtained from nationally 
available sources.51,55 Use of medication was 
valued using the price of drugs listed in the British 
National Formulary.56 Informal care was valued by 
the opportunity cost method suggested by Posnett 
and Jan.57 Average cost per day of critical care and 
ECMO was obtained from a separate study and 
weighted/adjusted for each centre in the CESAR 
trial (see Cost per day of ICU including ECMO 
unit care). Cost of visiting was also derived from 
a separate study (see Costs of visiting patients in 
intensive care).
Costs of private travel were estimated using 
Automobile Association (AA)55 motoring costs, 
which publishes the average cost per mile for petrol 
cars annually.
Valuation of informal care time
In the CESAR trial, informal care time was valued 
using Posnett and Jan’s57 scenarios: working 
time where output is replaced; working time 
where output is not replaced; non-work time of 
those in paid employment and those not in paid 
employment; and, finally, for those not in paid 
employment where unpaid housework is not 
replaced. Average wage rates for men and women 
in the UK needed for estimating time costs were 
obtained from the Office of National Statistics.53
Predicted future costs of lifetime care
It was assumed that for survivors at 6 months, 
costs of care would remain the same as they were 
at 6 months’ follow-up until 24 months post 
randomisation. At 24 months, the average health 
service expenditure for the surviving patients in the 
CESAR trial was assumed to be the same as that of 
similar age groups in the UK. The age groups used 
in predicting future costs and benefits were 16–44 
years and 45–64 years. Data on health services’ 
costs for these age groups have been published 
in the proceedings of Parliament.58 The same 
age groups were used as the basis for estimating 
patients’ long-term costs and their benefits.
Price year, inflation, currency and 
discounting
Resources and costs were measured in the year in 
which they occurred using appropriate unit costs 
for each year of resource use. All costs were then 
revalued for analysis and reporting to 2005 UK 
values using health-care inflation estimates.
The duration of follow-up for the short-term 
analyses was 6 months and therefore discounting 
was not necessary. For capital costing, annualised 
values were used based on previous experience with 
earlier pilot studies relating to the Critical Care 
National Cost Block study.59 All costs were based on 
the 2005 price year. For the lifetime estimates, costs 
and QALYs were discounted at 3.5%, based on UK 
treasury guidelines.60
Cost per day of ICU including 
ECMO unit care
This was a prospective, observational, longitudinal 
multicentre study (the Critical Care ICU HRG 
study), concurrent with the CESAR trial, involving a 
volunteer sample of 70 critical care units, in which 
monthly data on critical care unit expenditure 
together with daily data on patients’ organ support 
were collected for a 3-month period.51 The sample 
had good geographical coverage in England, with 
smaller numbers from Scotland and Northern 
Ireland but none from Wales. An average daily cost 
of an ICU was estimated by collecting data on the 
annual expenditure of ICUs and apportioning this 
sum by their annual throughput of patients.
Data collection
The critical care units and hospital finance 
departments were sent questionnaires to document 
their monthly expenditure on consumables (drugs 
and fluids, disposable equipment, nutritional 
products and blood and blood products), staff 
(consultant medical staff and other medical staff), 
clinical support services (radiology tests and 
laboratory services), their use of professionals 
allied to medicine (physiotherapists, clinical 
pharmacists, dieticians, medical technical officers, 
information technologists, clinical and biomedical 
scientists, speech and language therapists, clinical 
psychologists and occupational therapists), 
support staff (personnel officers and directorate 
accountants) and specialised bed therapy. Data 
were also collected on the monthly number of 
patient days, number of staffed beds, number of 
patient admissions, etc. An average daily cost was 
calculated using the following formula:
Monthly number of total patient days
(Monthly expenditure on staff + consumables
+ clinical support services) ∑
Internal validation of the cost data collected was 
not performed; however, external validation of the 
estimates was possible using data from the Critical 
Care National Cost Block Programme.59 Twenty-DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
13
one units in this study (30%) contributed data to 
the Cost Block Programme for the financial year 
2000–1. Although the Cost Block Programme 
collected data for a different time period and using 
a different configuration of units, the similarity 
between the mean costs per patient day is striking, 
in particular the costs of consumables and clinical 
support services. The study by Hibbert et al.51 
had wider coverage of resources with respect to 
professionals allied to medicine and an inbuilt 
allowance for capital equipment, which may be 
responsible for a slightly higher mean costs per 
day (£1302, 2003 price year) than for the Cost 
Block Programme (£1028, 2001 price year; £1119 
inflated to 2003 price year).
The completeness of the returned data was 
investigated by each resource item and expressed 
as a percentage of the number of responses divided 
by the total number of 18 possible responses. Data 
on nursing and administrative staff together with 
drugs and fluids yielded the highest number of 
responses (77%). Data on clinical and biomedical 
scientists and clinical psychologists yielded the 
lowest number of responses at 14%.
The average daily cost in critical care has to be 
adjusted to reflect the severity of illness or degree 
of organ support required by patients. For this 
purpose data provided by 46 critical care units in 
the Critical Care ICU Healthcare Resource Group 
(HRG) study51 were used. Only those critical care 
units that supplied data on their expenditure, 
organ support and unit characteristics were 
included. The aim was to develop an appropriate 
model from which estimates of daily case-mix 
adjusted costs could be determined. Different ways 
of modelling the organ support and expenditure 
data were explored. The model of choice was 
informed by the Breusch-Pagan and Hausman 
specification tests61 that favoured a random effects 
model based on the number of organs supported 
on a daily basis, clustered to include zero or one 
organs, two organs, and three or more organs. This 
model offered a simple and reproducible system 
of estimating case-mix adjusted costs of care. Daily 
organ support weights were 0.577 for zero or one 
organs supported, 1.137 for two organs supported 
and 1.156 for three or more organs supported.62 
These weights were applied to average daily costs 
of patients participating in the CESAR trial. A 
total cost per patient of his or her ICU stay was 
calculated by weighting patients’ average daily cost 
according to the number of organs supported on a 
daily basis and summing these daily costs for each 
patient.
Not all CESAR centres took part in the Critical 
Care HRG costing study. Separate visits or contacts 
by correspondence were made with all CESAR 
centres that did not participate in the Critical Care 
HRG costing study, including the ECMO centre, 
to collect the same data to estimate the daily cost 
in the same way. The response rate of the control 
centres was low with only 16% of questionnaires 
returned. In order to estimate average daily costs 
for each CESAR hospital for the financial year in 
which a patient(s) was treated, missing data were 
substituted with mean estimates obtained from 
the responding hospitals by financial year. A more 
thorough description of this part of the research is 
included in Clare Hibbert’s PhD Thesis.63
Costs of visiting patients in 
intensive care
A pilot study of the costs of visiting64 was carried 
out in December 2001 at an ICU in the UK. The 
pilot study informed the methods for a multicentre 
study in six ICUs in the UK that were registered 
with the CESAR trial. The aim was to estimate the 
average cost of visiting patients in intensive care. 
All adults including primary carers visiting the 
ICUs during a 3-week period were requested to 
complete a questionnaire that asked them about 
their time spent in visiting and travel, out of pocket 
expenses, employment status, loss of income, etc. 
Data from this study were used to estimate the 
average cost of visiting per day.
Analysis and reporting 
of costs and economic 
evaluation
Estimation of costs for each 
patient
Costs falling upon the health sector (health and 
social services), costing failing upon patients/
families and other costs, such as help from friends, 
were presented in total and disaggregated. 
Resource use and unit costs described above were 
used to estimate mean, medians, SDs and ranges of 
costs for each patient in the CESAR trial.
Cost-effectiveness analysis
With the availability of patient level data on costs 
and effects, it is possible to summarise uncertainty 
in the incremental cost-effectiveness ratio as a 
confidence interval (CI). The focus here is to 
estimate the CIs for incremental cost-effectiveness Methods
14
ratios when uncertainty is limited to the north-east 
quadrant of the cost-effectiveness plane (i.e. when 
the new treatment under evaluation is significantly 
more costly and more effective). Non-parametric 
bootstrapping was used to generate CIs.
Cost–utility analysis
Lifetime incremental cost–utility ratios were 
estimated using Monte Carlo simulation methods 
in a simple decision-analytic model,65,66 and using 
data and simplifying assumptions described above.
Sensitivity analysis and 
uncertainty
Sensitivity analysis based on testing specific 
assumptions and probabilistic analysis were used to 
explore the uncertainty in the results.67,68 Some of 
the items tested in the sensitivity analysis are listed 
in Table 2.
Primary analysis was on a complete case basis, 
whereby a complete case was defined as those 
meeting the CESAR trial clinical effectiveness 
data analysis. Any missing values were replaced 
with imputed values and reanalysed as part of the 
sensitivity analysis. Missing EQ-5D responses were 
imputed for the 6-month cost–utility analysis. In 
the best case all missing values were given perfect 
health (11111) and in the worst case all missing 
values given zero health (33333). However, this did 
not affect the results in any way. Missing EQ-5D 
responses were not imputed for the lifetime model.
Missing data were imputed using Rubin’s multiple 
imputation method69 with solas v3.20 (Statistical 
Solutions Inc., County Cork, Ireland).
TABLE 2  Items to test during sensitivity analysis
Item Ranges and thresholds
Days on ECMO Highest and lowest observations
Length of stay in critical care unit (ICU and high 
dependency unit)
Highest and lowest calculated costs
Total length of stay in hospital Highest and lowest calculated costs
Cost per day on organ support Highest and lowest calculated costs
Distance from ECMO centre (cost of transport) Replacing air with road transport
Change in difference in survival Upper and lower CI of the attributable benefit
Other items with significant cost difference Highest and lowest observationsDOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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Chapter 3  
Results
B
etween July 2001 and August 2006, enquiries 
were made about 766 potentially eligible 
patients from 148 centres. 180 of these patients 
(90 in each arm) were randomised from 68 
centres. Three patients in the conventional arm 
did not give permission to be followed up. These 
patients were alive and had been discharged from 
hospital but no reliable information is available 
regarding their level of disability 6 months after 
randomisation. Information about the primary 
outcome is available for 177 (98%) patients (Figure 
1). Table 3 shows that the groups were broadly 
comparable at trial entry in terms of key prognostic 
factors. Note that all of the 85 patients who entered 
the ECMO arm for hypoxia fulfilled the ARDS 
criteria according to the American–European 
Consensus.70 In the conventional arm, 87 patients 
entered the study based on hypoxia; 85 out of 87 
fulfilled the ARDS criteria and two the acute lung 
injury (ALI) criteria.
Table 4 shows the extent to which patients received 
their randomly allocated management. No patients 
allocated to CM received ECMO. However, one CM 
patient was put on an experimental form of lung 
support (Novalung®, Talheim, Germany), violating 
the protocol. Seventy-six per cent of patients 
allocated to transfer for consideration of ECMO 
were cannulated. Of those who did not receive 
ECMO, three died before transfer to Glenfield, 
two died in transit, 16 improved with conventional 
care, and one patient required amputation and 
could therefore not be heparinised. The 17 
patients who were transferred to Glenfield hospital 
by the ECMO transport team were managed by 
the ECMO team conventionally (i.e. attempting to 
achieve adequate gas exchange without excessive 
ventilator settings, predominantly FiO2 < 0.6, 
PIP < 30 cmH2O), using the same protocols as the 
ECMO patients with the exception that ECMO 
was not used. Table 4 includes information on 
compliance with the low volume ventilation 
strategy (defined as the number of patients in each 
arm who received low volume ventilation strategy 
at any time), and the mean proportion of days in 
critical care during which the strategy was followed 
for these patients. Both of these parameters were 
significantly higher in the ECMO arm than in the 
conventional arm (p < 0.001), indicating that more 
lung protective ventilation was used in the ECMO 
arm. As the proportion of total critical care days 
was used, this parameter was not affected by the 
lower number of critical care days in the control 
group.
Table 5 shows that fewer patients in the ECMO 
arm than in the CM arm had died before 6 
months (or later if before discharge home) or were 
severely disabled 6 months after randomisation, 
our primary end point [33/90 (36.7%) versus 
46/87 (52.9%); RR = 0.69 (95% CI 0.50 to 0.97); 
p = 0.030], i.e. six patients would need to be 
treated with ECMO to prevent one death or severe 
disability. Only one patient (in the CM arm) was 
known to be severely disabled at 6 months. This 
patient was unconscious and on an oscillator in 
hospital. Half of the CM patients and 36.7% of the 
ECMO patients died [RR = 0.73 (95% CI 0.50 to 
1.03); p = 0.07]. A greater proportion of deaths in 
the CM arm were classified as due to respiratory 
failure (Table 5).
The time from randomisation to death (Figure 2) 
was considerably shorter in the CM compared with 
the ECMO arm (log rank test 0.027).
Patients allocated to ECMO spent longer in critical 
care, and in hospital, than those allocated to CM, 
especially those who died (Table 6).
In the per-protocol analysis, 8 of the 22 patients 
allocated to ECMO but not receiving it died 
or were severely disabled (36.4%), a similar 
proportion to the 68 patients who did receive 
ECMO. Tables 7 and 8 describe these two groups 
and the CM groups in terms of the APACHE II 
(Acute Physiology and Chronic Health Evaluation 
II) score and the Murray score and its components 
at trial entry.
The mean APACHE II score at trial entry was 20, 
unfortunately 33 patients in the ECMO arm and 
29 patients in the conventional arm did not have 
an APACHE II form completed. The mean PaO2/
FiO2 ratio was 83.2 mmHg in the patients treated 
without ECMO versus 73.9 mmHg in those treated 
with ECMO (p = 0.24). This mean value does not 
give a true reflection of this patient group, some of Results
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Patients considered
potentially eligible for trial
N = 766
Not randomised N = 586
Randomised N = 180
Conventional ventilation N = 90 ECMO N = 90
Received ECMO
support N = 68
Did not receive
ECMO support N = 22
N = 90
N = 90 N = 90
N = 44
N = 46**
N = 3
N = 11
N = 32
N = 33
N = 57
N = 0
N = 5
N = 52
N = 87
Information available for
primary outcome
6-month follow-up
Died before 6 months
Eligible for 6-month follow-up
No information about
severe disability at 6 months
Information about 6-month
status based on limited
data from GP/hospital
Full 6-month assessment
Non-availability of ECMO bed N = 103
Murray score < 3 or pH > 7.2 N = 99
High pressure ventilation > 7 days N = 86
Other* N = 298
FIGURE 1  *81 were contraindicated to continue with treatment, 35 were only enquiries, 35 received advice on optimal conventional 
treatment, 33 refused assent, 31 had contraindications to limited heparinisation, 30 were aged < 18 or > 65 years; in 28 cases the clinician 
refused, eight had an improving condition, for seven the relatives were not available to provide assent, four died prior to randomisation, three 
had intracranial bleeding, two were given advice on ECMO treatment and one was ineligible due to earlier surgical treatment. **Includes 
one patient with follow-up assessment at 6 months in hospital and who died after 6 months without leaving hospital.DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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TABLE 3  Information at baseline
Random allocation
ECMO (N = 90) CM (N = 90)
Hospital of trial entrya
CTC 73 75
RH 17 15
Gender
Male  51 53
Age (years)a
18–30 25 23
31–45 29 32
46–65 36 35
Mean (SD) 39.9 (13.4) 40.4 (13.4)
Primary diagnosis at entrya
Pneumonia 56 53
Obstetric ARDS 0 0
Other ARDS 25 26
Trauma including surgery within 24 hours 5 7
Other 4b 4c
Number of organs faileda
l–2 62 63
≥ 3 28 27
Duration of IPPV at entry (hours)
0–48 46 51
49–168 36 32
> 168 6 7
Median (IQR) 35.0 (17.3 to 104.5) 37.0 (15.5 to 101.5)
Missing 2 0
Duration of high-pressure ventilation and/or high FiO2 at entry (days)a
0–48 56 59
49–168 34 31
Median (IQR) 28.5 (17.0 to 69.3) 28.0 (12.0 to 88.0)
Entry based on
a) Hypoxiaa 85 87
If yes, Murray score mean (SD) 3.5 (0.6) (0.3)
Components of Murray score
PaO2/FiO2 mean (SD) 75.9 (29.5) 75.0 (35.7)
PaO2/FiO2 median (IQR) 73 (57.5 to 87.0) 70.5 (60 to 88)
PEEP mean (SD) 13.7 (9.6) 14.2 (9.4)
Lung compliance mean (SD) 27.4 (12.2) 25.3 (8.0)
Chest radiograph mean (SD) 3.5 (0.7) 3.7 (0.6)
b) Uncompensated hypercapnoeaa 5 3
If yes, pH mean (SD) 7.1 (0.1) 7.1 (0.1)
a  Minimisation criteria. 
b  Asthma; Weil’s disease; dermatomyositis; pancreatitis.
c  Asthma; aspiration; asthma/bronchospasm; acute miliary tuberculosis.Results
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TABLE 4  Actual management after randomisation
Actual management
Random allocation
ECMO (N = 90) CM (N = 90)
ECMO received  68a 0
Type of transport to ECMO centre
Air (± ground) 24
Ground 38
Not transferred 6b
Time between randomisation and starting (hours) – median (IQR) 6.1 (4.0 to 7.1)c
Duration of ECMO (days) – median (IQR) 9.0 (6.0 to 16.0)d
Conventional management (IPPV)
Transferred for conventional management after randomisation 22a 11
Type of transport to conventional centre
Air (± ground) 5 2
Ground  14 9
Not transferred  3 79
Duration of IPPV after randomisation (days) – median (IQR) 10 (4.8 to 22.8) 11 (4.0 to 20.3)
Other managements after randomisation
Missing all data 2
High frequency/oscillation or jet ventilation 6 13
Nitric oxide  9 6
Prone position 32 38
Steroids 76 58
MARS 15
Continuous venovenous haemofiltration 72 76
Low volume ventilation strategy at any time 84 63
Proportion of days under low volume ventilation strategye – mean (SD) 0.86 (0.17) 0.67 (0.32)
a  Of those who did not receive ECMO, 16 improved with conventional care, three died before transfer to Glenfield, two 
died in transit and one patient required amputation and could therefore not be heparinised.
b  Already in the ECMO centre receiving conventional treatment.
c  N = 66. Includes one patient whose condition improved on arrival at the ECMO centre so was managed conventionally 
but then 10 days later deteriorated and ECMO was started.
d  N = 67. Includes three patients who had a second course of ECMO.
e  Based on those under low volume ventilation strategy at all.
whom were so sick that they died before or during 
transfer and the remainder were not considered 
sick enough to warrant ECMO by the ECMO team.
In further stratified analyses as specified in the 
protocol, no significant interactions between the 
minimisation criteria and the treatment group 
with respect to the primary outcome were found 
(Table 9).
Table 10 provides further information about the 
6-month follow-up assessment. The first two EQ-
5D questions (mobility and self-care) were used to 
define severe disability in our primary outcome, 
and answered by proxy for five patients in ECMO 
and seven in CM, hence missing values are less 
than the other components of EQ-5D and other 
elements of the follow-up assessment. None of 
the differences between groups were statistically 
significant at the 5% level.
The time from randomisation to death (Figure 2) 
was considerably shorter in the CM than in the 
ECMO arm (log rank test 0.027).DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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TABLE 5  Primary outcome
Allocation
ECMO (N = 90) CM (N = 90) RR (95% CI)
Death or severe disability at 6 months
No 57 41
Yes 33 46 0.69 (0.05 to 0.97)
(p = 0.03)a
No information about severe disability at 6 months 0 3
Died ≤ 6 months or died before discharge
No 57 45
Yes 33 45 0.73 (0.52 to 1.03)
(p = 0.07)
Severe disability
Yes 0 1
No 57 41
Died ≤ 6 months before discharge 33 45
No information about severe disability at 6 months 0 3
Cause of death
Respiratory failure 8 24
Multi-organ failure 14 15
Neurological 4 2
Cardiovascular 1 3
ECMO related 1 0
Other 1 0
Unknown 4 1
Randomisation to death interval (days)
Median (IQR) 15 (3.0 to 40.5) 5 (2 to 14)
a  Based on 187 patients with known primary outcome. The three patients in the CM group for whom the severe 
disability status at 6 months was unknown had all been discharged from hospital 1–3 months post randomisation and 
were known to be alive at 6 months. Sensitivity analyses assuming that these three patients had all been or not been 
severely disabled change these figures to RR = 0.67 (95% CI 0.48 to 0.94), p = 0.017, and RR = 0.72 (95% CI 0.51 to 1. 01), 
p = 0.051 respectively.
Economics results
Resource use data were collected for all patients 
included in the CESAR trial, so costs could be 
estimated for all participants. Although final 
primary outcome data for clinical effectiveness 
were available from all but three patients, complete 
EQ-5D data were missing in 17 cases.
Table 11 shows that patients allocated to ECMO 
were transported further for care and so used more 
transport. There was also a trend for them to have 
more organ systems supported and to stay longer 
in hospital than those allocated to CM. Surviving 
patients allocated to ECMO and returning home 
required more nursing and other therapy and 
social services, per patient, than those receiving 
CM, but the mean differences were not statistically 
significant. All other health-care use was similar 
between groups.
Table 12 shows that the majority of costs incurred 
were for health care, and the highest care costs 
resulted from the initial hospitalisation. Both 
groups of patients surviving to hospital discharge 
had considerable time given by family and friends, 
amounting to a value of £4332 per patient in the 
ECMO group, and £2212 in the CM group. This Results
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TABLE 7  Primary outcome and APACHE II scores
ECMO: yes (N = 68) ECMO: no (N = 22) CM (N = 90)
Death or severe disability
Yes 25 8 46
No  43 14 41
Missing 3
APACHE II score
Mean (SD) 20.5 (7.0) 18.2 (3.5) 19.9 (6.1)
Missing 27 6 29
TABLE 6  Length of stay
ECMO (N = 90) CM (N = 90)
Days in critical care – median (IQR) 24.0 (13.0 to 40.5)a 13 (11 to 16)
Days in hospital – median (IQR) 35.0 (15.6 to 74.0) 17.0 (4.8 to 45.3)
Deaths only N = 33 N = 45
Days in critical care – median (IQR) 11a (2 to 28) 5.0 (2.0 to 13.5)
Days in hospital – median (IQR) 15 (3.0 to 40.5) 5.0 (2.0 to 13.5)
a  Excludes one patient whose notes are still with the coroner.
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TABLE 8  Murray scores and components
ECMO: yes ECMO: no CM
Entry based on hypoxia (n) 65 20 87
Murray score mean (SD) 3.4 (0.3) 3.6 (1.3) 3.4 (0.3)
Components of Murray score
PaO2/FiO2 mean (SD) 73.8 (29.9) 83.2 (27.7) 75.0 (35.7)
PaO2/FiO2 median (IQR) 70.0 (55.5 to 87) 80 (62 to 105) 70.5 (60 to 88)
PEEP mean (SD) 14.5(11.0) 11.5 (2.1) 14.2 (9.4)
Lung compliance mean (SD) 27.1 (13.0) 28.4 (9.9) 25.3 (8.0)
Chest radiograph mean (SD) 3.5 (0.7) 3.5 (0.8) 3.7 (0.6)
TABLE 9  Stratified analyses by minimisation factors
Severe disability or death by 6 months
Minimisation factor ECMO n/N (%) CM n/N (%) RR
p-value 
(for interaction test)
Hospital of trial entry
CTC 30/73 (41.1) 38/73 (52.1) 0.79 (0.56 to 1.12) 0.12
RH 3/17 (17.7) 8/14 (57.1) 0.31 (0.10 to 0.95)
Age (years)
18–30 8/25 (32.0) 12/22 (54.6) 0.59 (0.30 to 1.17) 0.20
31–45 7/29 (24.1) 15/31 (48.4) 0.50 (0.24 to 1.05)
46–65 18/36 (50.0) 19/34 (55.9) 0.89 (0.57 to 1.39)
Primary diagnosis at entry
Pneumonia 21/56 (37.5) 29/51 (56.9) 0.66 (0.44 to 1.00)
Other ARDS 8/25 (32.0) 14/25 (56.0) 0.57 (0.29 to 1.11)
Trauma including surgery within 
24 hours
2/5 (40.0) 1/7 (14.3) 2.8 (0.34 to 23.06)
Other  2/4 (50.0)  2/4 (50.0)  1 (0.25 to 4.0)  0.59
Number of organs failed
1–2 15/62 (24.1) 27/60 (45.0) 0.54 (0.32 to 0.91) 0.10
≥ 3 18/28 (64.3) 19/27 (70.4) 0.91 (0.63 to 1.32)
Duration of high pressure ventilation and/or high FiO2 at entry (hours)
0–48 21/56 (37.5) 28/57 (49.1) 0.76 (0.50 to 1.17) 0.56
49–168 12/34 (35.3) 18/30 (60.0) 0.59 (0.34 to 1.01)
Mode of trial entry
Hypoxic 31/85 (36.5) 44/84 (52.4) 0.70 (0.49 to 0.98) 0.83
Hypercarbic 2/5 (40.0) 2/3 (66.7) 0.60 (0.16 to 2.29)Results
22
TABLE 10  Six-month follow-up assessment
ECMO (N = 90) CM (N = 90)
Alive at 6 months or discharged alive  57 46
Full follow-up information available 52 32
Limited information from GP/hospital  5 8
Information on death and disability status only 0 3
Alive but no further information available 0 3
EQ-5D 57 40
Problems with mobility
No problems in walking about 30 19
Some problems in walking about 26 19
Confined to bed 0 2
Missing 1a 0
Problems with self-care
No problems with self-care  42 26
Some problems washing or dressing myself 13 11
Unable to wash or dress myself 2 2
Missing  1a 1b
Follow-up information available 52 33
Usual activities
No problems with performing usual activities 21 10
Some problems with performing usual activities 25 19
Unable to perform usual activities 6 4
Pain/discomfort 
No pain or discomfort  23 13
Moderate pain or discomfort 22 18
Extreme pain or discomfort 7 2
Anxiety/depression
Not anxious or depressed  23 21
Moderately anxious or depressed 26 9
Extremely anxious or depressed 3 3
Overall health status (visual analogue scale)(higher score indicates better health)
Mean (SE) 67.9 (2.8) 65.9 (3.8)
Missing 0 1
Compared with a year ago
Better now 9 2
Somewhat better now 5 2
About the same 9 5
Somewhat worse now 18 13
Much worse now 11 9
Missing 0 1
SF-36 – mean (SE) (higher = better)
Physical functioning 64.5 (4.2) 60.0 (5.9)
Missing 2a 1
Role: physical 58.2 (4.8) 46.3 (6.5)
Bodily pain 66.2 (4.2) 62.2 (5.0)DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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ECMO (N = 90) CM (N = 90)
General health 54.1 (3.0) 49.3 (3.9)
Vitality 52.9 (3.3) 47.7 (4.1)
Social functioning 69.5 (3.9) 62.1 (5.7)
Role: emotional 72.6 (4.3) 71.4 (5.6)
Mental health 70.5 (3.0) 65.5 (3.7)
St George’s Hospital Respiratory Questionnaire – mean (SE) (higher = worse)
Symptom score 32.4 (3.3) 41.2 (4.5)
Missing 0 1
Activity score 29.5 (3.7) 38.4 (5.4)
Missing 2a
Impacts score 15.0 (2.4) 18.8 (3.1)
Total score 22.4 (2.7) 27.6 (3.6)
Missing 2a 1
Mini-Mental State Examination – mean (SE) (lower value = more 
problems with cognition)
28.6 (0.3) 28.0 (0.5)
Below normal (< 24) 2 2
Missing 3b 1
HADS depression score – mean (SE) (higher value = more depression) 4.4 (0.6) 5.8 (0.7)
Significant depression (score 11–21) 4 4
Missing 2 0
HADS anxiety score – mean (SE) (higher value = more anxiety) 5.8 (0.6) 7.4 (0.8)
Significant anxiety (score 11–21) 7 10
Missing 2 0
Sleep problems score – mean (SE) (higher = more problems) 16.7 (3.2) 18.8 (3.6)
Caregiver strain index
Low 8 2
High (score 7 or more) 9 6
Missing  2b 0
Not applicable (no carer) 33 24
Restrictions to upper limb movement 3 5
Missing 2b 1
Lung capacity – mean (SE)
FEV1 (litres) 2.6 (0.1) 2.5 (0.1)
FEV1% of predicted 74.9 (2.0) 72.9 (3.3)
FVC (litres) 3.3 (0.1) 3.2 (0.2)
FVC % of predicted 79.6 (2.4) 79.9 (3.6)
FER (%) 81.9 (1.5) 81.6 (2.2)
FER% of predicted 101.0 (1.7) 100.7 (2.5)
PEFR (litres/minute) 370.7 (16.1) 364.3 (20.5)
PEFR % of predicted 74.5 (2.4) 75.1 (3.6)
Missing 3 2
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FER, forced expiratory ratio; HADS, Hospital Anxiety 
and Depression Scale; PEFR, peak expiratory flow rate.
a  One patient in a wheelchair and did not answer mobility question, and one patient had limited mobility so left out those 
sections.
b  Severe alcohol-related problems so very limited follow-up available.
TABLE 10  Six-month follow-up assessment (continued)Results
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TABLE 11  Use of health-care services by patients in the CESAR trial 
ECMO (N = 90) CM (N = 87)
Difference,  
mean (95% CI) Total Mean Total Mean
Resource use from trial entry to discharge from hospital
Air ambulance (miles) 5538.98 61.54 605.50 6.96 54.58 (26.74 to 82.43)
Road ambulance (miles) 22,797.96 253.31 6412.81 73.71 179.60 (121.92 to 237.28)
0–1 organs supported (number of days) 1380 15.33  1095 12.59 2.75 (–2.35 to 7.84)
2 organs supported (number of days) 627 6.97  478 5.49 1.47 (–1.28 to 4.23)
≥ 3 organs supported (number of days) 750 8.33  426 4.9 3.44 (–0.44 to 7.32)
Other hospital stay (number of days) 1607 17.86  1329 15.28 2.58 (–5.25 to 10.41)
Resource use from discharge to follow-up at 6 months
Travel home after discharge (miles) 914.40 10.16  70 0.80 9.36 (0.45 to 18.26)
GP surgery services (times) 173 1.92 188 2.16  –0.24 (–1.21 to 0.73)
Telephone calls to NHS professionals 
(times)
19 0.21  50 0.57 –0.36 (–1.11 to 0.39)
Visits to nurse (times) 357 3.97 309 3.55  0.41 (–4.53 to 5.36)
Visits to physiotherapist (times) 240 2.67  246 2.83  –0.16 (–3.83 to 3.51)
Visits to occupational therapist (times) 65 0.72  14 0.16  0.56 (–0.17 to 1.30)
Counselling (times) 11 0.12  21 0.24  –0.12 (–0.55 to 0.31)
Other nursing, therapy and social 
services (times)
425 4.72  21 0.24 4.48 (–3.59 to 12.55)
Inpatient stay (days) 122 1.36 63 0.72  0.63 (–1.03 to 2.29)
Outpatient visits (times) 121 1.34 104 1.21 0.14 (–0.50 to 0.77)
Other hospital services (times) 12 0.13  84 0.97  –0.83 (–3.13 to 1.46)
Nursing home and residential care (days) 3.43 0.04  9 0.10  –0.07 (–0.28 to 0.15)
Help/support from family/friends (hours) 29,198.5 324.43 14,388 165.38 159.05 (–12.99 to 331.08)
excludes the costs of visiting during the initial 
hospital stay (see below for results of the survey of 
costs of visiting)
Mean health-care costs per patient were more 
than twice as high for the patients allocated to 
ECMO (£73,979) than for those allocated to CM 
(£33,435), a difference of £40,544 (95% CI £24,799 
to £56,288). As is usual, health-care costs were quite 
skewed and highly variable between patients.
Based on a simple budget impact analysis, and 
using the same costing assumptions listed above, 
we have estimated that the additional cost to the 
health service of a policy of providing access to 
the ECMO service would be £4,828,320 per year 
for 120 patients and £14,082,600 per year for 350 
patients.
Cost-effectiveness analysis
The base-case analysis (from the NHS viewpoint 
and so excluding patients’ costs) found the 
incremental cost-effectiveness of ECMO to be 
£250,162 per additional survivor without severe 
disability. Table 13 also presents the results of the 
sensitivity analysis for alternative methods for cost 
estimation.
Cost–utility analysis
Table 14 reports the incremental cost–utility ratios 
for different scenarios from the NHS viewpoint, 
illustrating the results of the cost–utility analysis 
according to changes in the key assumptions. 
The mean gain in QALYs at 6 months post DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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TABLE 12  Costs per CESAR trial participant (2005 prices)
ECMO (N = 90), 
mean (£)
CM (N = 87), 
mean (£)
Cost difference,  
mean (95% CI) (£)
Recruitment to discharge
Air ambulance 2175 425 1750 (891 to 2609)
Land ambulance plus staff 815 205 609 (484 to 734)
Cost of 0–1 organs supported 20,542  10,260 10,281 (4730 to 15,834)
Cost of 2 organs supported 19,590 8939 10,652 (4428 to 16876)
Cost of ≥ 3 organs supported 24,928 7986 16943 (7742 to 26,143)
Cost of other hospital stay 5531 4732 799 (–1672 to 3270)
Discharge to 6 months
Travel home after discharge 18 1 16 (0.44 to 32)
GP surgery services 59 64 –5 (–36 to 26)
Phone calls to NHS professionals 4 11 –7 (–20 to 7)
Visits to nurse 85 73 12 (–67 to 92)
Visits to physiotherapist 118 124 –6 (–138 to 126)
Visits to occupational therapist 25 6 19 (–0.41 to 39)
Counselling services 8 5 4 (–8 to 15)
Other nursing, therapy and social services 78 10 68 (–37 to 173)
Inpatient stay 420 224 196 (–328 to 719)
Outpatient visits 125 113 13 (–47 to 72)
Other hospital services 9 93 –84 (–198 to 31)
Nursing home and residential care 20 39 –19 (–104 to 67)
Medication 119 88 31 (–106 to 168)
Aids and adaptations 19 6 12 (–8 to 33)
Hospital transport – discharge to follow-up 5.39 5.65 –0.3 (–10 to 9)
Unpaid help from family/friends 4332 2212 2119 (–139 to 4377)
randomisation for those patients allocated to 
ECMO was 0.03 (95% CI 0.00 to 0.06) and the 
cost per additional QALY at 6 months post 
randomisation was £1,631,124.
Individual patient costs were estimated using the 
number of days at different levels of critical care, 
and the national NHS prices as the source of unit 
cost (rather than the number of days at different 
levels of organ support and unit costs obtained 
from participating centres) are shown in scenario 2 
in Tables 13 and 14, and in both cases reduce costs 
per outcome gained from the ECMO treatment 
option.
The predicted lifetime incremental cost per QALY 
discounted at 3.5% (scenario 3 in Table 14) was 
£19,252 (95% CI £7622 to £59,100). If discount 
rates were assumed to be zero (that is, future 
values are worth the same as current values), total 
costs and total QALY gain were both higher, and 
the cost–utility of ECMO improves (scenario 4 in 
Table 14).
There is considerable uncertainty in these 
estimates, as the confidence limits in Table 14 show.
Figure 3 illustrates the cost-effectiveness 
acceptability curve for lifetime estimates,68 showing 
the probability (vertical axis) that a policy of ECMO 
would be cost-effective at different thresholds of 
willingness to pay at 2005 prices (horizontal axis). 
This shows that ECMO has a more than 50% 
chance of being cost-effective at any threshold of 
spending over around £20,000.Results
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TABLE 14  Cost–utility analysis results for CESAR trial (bootstrap estimates)
Scenario QALYs gained Additional cost (£) ICER (95% CI) (£)
1a 0.03 44,191 1,631,124 (–3,242,953 to 11,463,378)
2b 0.03 26,772 732,818 (223,832 to 491,808)
3c 3.66 48,533 19,252 (7622 to 59,100)
4d 7.01 53,896 9389 (4580 to 31,877)
a  Outcome – QALYs gained at 6 months, costs based on primary research study (see text).
b  Outcome – QALYs gained at 6 months, costs based on NHS tariffs (see text).
c  Lifetime predicted costs and QALYs, discounted at 3.5%.
d  Lifetime predicted costs and QALYs, undiscounted.
FIGURE 3  Cost-effectiveness acceptability curve – lifetime estimates discounted at 3.5%.
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TABLE 13  Cost-effectiveness of allocation to ECMO compared with conventional management
Scenario
ECMO CM
ICERb (£)
Mean 
cost (£) 
(N = 90)
Survival 
(years)a 
(N = 90)
Mean 
cost (£) 
(N = 87)
Survival 
(years)a 
(N = 87)
1: base casec 73,979 0.63 33,435 0.47 250,162 
2d 57,534 0.63 36,688 0.47 128,621 
a  Probability of survival to 6 months.
b  Incremental cost-effectiveness ratio (difference in costs/difference in effects).
c  Total days spent in critical care grouped into three categories based on number of organs supported: 0–1 organs, 2 
organs and ≥ 3 organs, and valued accordingly. Average unit costs applied for all other resource use.
d  Total days spent in critical care grouped into three categories: ECMO days, ICU days and high dependency unit days, and 
average costs applied. Average unit costs applied for all other resource use.DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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Results of costs of visiting 
study
A total of 334 visitors visited the six ICUs over the 
3-week period. Of these, 17 visitors refused to take 
part in the study, 24 visitors had to be excluded 
under the exclusion criteria and 77 visitors could 
not be recruited for other reasons. Information 
leaflets and questionnaires were given out to the 
remaining 216 visitors and 173 questionnaires were 
returned (response rate 80% of eligible visitors).
Table 15 shows the characteristics of respondents. 
Visitors were mainly close family members and 
relatives (95%) who came almost daily until the 
patient’s discharge. Some made multiple visits 
at different times during the same day. Relatives 
spent several hours by the bedside talking to 
patients, reading out letters/newspapers, showing 
photographs, and sometimes alerting the nurse 
to changes in the patient. Some helped with 
minor tasks such as wiping the patient’s face and 
adjusting the blanket. Personal care such as body 
baths, changing bed sheets, etc. was carried out by 
nursing staff.
Out of pocket expenses
The out of pocket expenses incurred by visitors 
were those related to travel, car parking, child care, 
accommodation and refreshments.
Travel
Visitors travelled a mean distance of 29.97 miles 
(one-way) to the ICU; range 0.25–31,000 miles. 
The distribution was skewed to shorter journeys, 
indicated by the range and a median value of 10 
miles (Table 16).
One hundred and sixteen visitors (67%) travelled 
by their own car, with a further 39 (23%) sharing 
a car with a friend/relative. The total number 
of people who travelled by car was 155 (90%). 
Fifty-eight (58) visitors (34%) paid parking fees. 
Thirteen visitors (8%) travelled by taxi, bus or 
train, three (2%) travelled by plane and two (1%) 
walked. The distance between home and ICU is 
heavily skewed because of five visitors who travelled 
from abroad.
Cost of private car travel was calculated using 
published AA motoring costs for price year 2005. 
The estimate used for this study was £0.3578 per 
mile, which includes standing and running costs 
for a new petrol car priced between £10,000 and 
£13,000, with annual mileage 15,000, and the 
average cost of unleaded petrol for 2005 which was 
£0.878 per litre.
Child care, care of dependent 
relatives and care of pets
Thirty-three visitors (19.1%) had to arrange child 
care. Of these, two (1.2%) paid for child care, three 
(1.7%) brought their children with them and 28 
(16.2%) made arrangements with relatives. Eight 
(4.6%) visitors arranged care for other dependent 
relatives with other relatives or friends. Thirty 
(17.3%) visitors arranged care for their pets. Of 
these, 27 (15.6%) made arrangements with relatives 
and three (1.7%) paid for care.
Accommodation
Thirty-five visitors (19.4%) needed overnight 
accommodation. The reasons for this were 
distance of ICU from home and the severity of the 
patient’s condition. Of these, only nine paid for 
TABLE 15  Visitor characteristics (N = 173)
Gender
Male 58 (34%) 
Female 113 (65%)
Missing data 2 (1%)
Age
Range 18–85 years
Mean 49.3 years
Median 48 years
Visitors < 65 years 144 (83%)
Visitors ≥ 65 years 26 (15%)
Visitors in paid employment 104 (61%)
Incomplete data 3 (1.7%)
Relationship to patient
Spouse/partner 47 (28%)
Close relatives (children, parents) 90 (53%)
Other relatives 25 (15%)
Friends/neighbours 9 (5%)
Incomplete data 3 (1.7%)
Percentages are based on total of valid responses to 
each question.Results
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TABLE 16  Distance travelled by visitors (N = 173)
Range (miles) Mean (miles) Median (miles) SD (miles)
Distance between home and ICU 0.25–31,000 29.97 10.1 2425.01
TABLE 17  Out of pocket expenses (N = 173) (pounds sterling at 2005 prices)
Numbers (%) Range Mean Median SD 95% CI
Travel: own car  
(standing and running costs)
116 (67%) 0–214.7 15.0 2.3 31.9 10.2 to 19.8
Travel: bus, taxi, train 13 (8%) 0–600 10 0 56.6 1.5 to 18.5
Parking fees 57 (33%) 0–14 1.2 0 2.2 0.8 to 1.5
Travel: plane 3 (2%) 0–3400 35.3 0 303.5 –10.2 to 80.9
Accommodation 35 (19.4%) 0–179 2.6 0 15.7 0.3 to 5.0
Child care and care of pets 71 (41%) 0–50 0.92 0 5.9 0.05 to 1.8
Food and drinks  100 (57.8%) 0–40 4.5 1 8.0 3.3 to 5.7
TABLE 18  Average out of pocket and travel costs per participant (N = 173) (pounds sterling at 2005 prices)
Range Mean Median SD 95% CI
Total out of pocket expenses including air travel 0–3423 69.5 9.2 310.1 22.9 to 116.02
Total out of pocket expenses excluding air travel 0–600 34.2 9.2 69.8 23.7 to 44.6
accommodation, the remaining 26 answered ‘not 
applicable’ to the question regarding payment.
Refreshments
One hundred people (57.8%) purchased food or 
drinks. Five visitors (2.9%) did not answer this 
question.
The mean out of pocket expenses of the 173 study 
participants are shown in Tables 17 and 18.
Visitors were asked about activities forgone 
(activities they would have been doing) for the visit 
and leave arrangements for those in employment 
(Table 19). Participants could indicate more than 
one category, so totals add to more than the total 
number of respondents. Of the 173 participants, 
104 (60.1%)  were in paid employment, one 
in voluntary work (1%), 41 (23.7%) doing 
housework, 33 (19.1%) retired and the remaining 
12 (6.9%) engaged in other activities. Of those 
in employment, 24 (23.3%) took annual leave, 
28 (27.2%) had obtained compassionate leave, 
13 (12.6%) took unpaid absence from work, 32 
(31.1%) came outside of their work time and six 
(5.8%) intended to make the time up. Table 20 
shows the daily time forgone by visitors for the visit 
and the actual time spent with the patient.
Total time forgone was estimated as the difference 
between time of leaving home and the time 
expected to be back home (Table 20). Average costs 
of this time forgone are shown in Table 21.DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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TABLE 19  Activities forgone and leave arrangements
Number Percentage
Category of activities (N = 173)a
Working in paid employment 104 60.1
Voluntary work 1 0.6
Housework 41 23.7
Other 12 6.9
Retired 33 19.1
Leave arrangements (N = 104)
Took annual leave 24 23.3
Compassionate leave 28 27.2
Unpaid absence 13 12.6
Will make time up 6 5.8
Came outside of work time 32 31.1
a  Participants could indicate more than one category, so totals add to more than the total number of respondents.
TABLE 20  Time forgone (N = 173) (hours)
Range Mean Median SD
Total time forgone for the visit 0.20–24a 6.6 5.0 5.8
Time spent with patient 0.05–24a 3.9 2.2 5.0
a  Maximum time 24 hours because the study looked at daily time forgone by visitors. In a day, time cannot be more than 24 
hours.
TABLE 21  Average cost of time forgone and lost pay (N = 173) (pounds sterling at 2005 prices)
Daily costs Range Mean Median SD 95% CI
Cost of time forgone  1.7–255.8 59.6 40.2 55.5 51.3 to 68.0
Lost income due to unpaid 
leave
0–206.4 6.9 0 29.2 2.5 to 11.2DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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Chapter 4  
Discussion
Clinical effectiveness
This study showed an important improvement in 
outcome when a strategy of transferring patients to 
a specialist centre for consideration of ECMO was 
used to manage adults with severe but potentially 
reversible respiratory failure rather than continued 
conventional ventilation. As hypothesised, transfer 
for consideration of ECMO reduced the proportion 
of patients who died or were severely disabled 6 
months after randomisation by approximately 
one-third compared with those in the conventional 
arm [although the rate in the control arm (52.9%) 
was lower than expected in the second power 
calculation (65%)]. The primary outcome measure 
that the trial was powered to detect was a difference 
in death or severe disability at 6 months post 
randomisation. Whilst this is a composite end 
point, it addresses failings of previous studies 
by detecting late deaths and also ensures that 
the survival is meaningful from a societal and 
individual standpoint. The hospital mortality was 
also lower in the ECMO arm, although it did not 
reach statistical significance, but this was not what 
the study was powered to detect. The APACHE II 
score is commonly used to estimate disease severity 
and is a predictor of mortality in patients with 
ARDS.71,72 The reported APACHE II score in case 
series of patients with ARDS varies significantly, 
ranging between 13.4 and 28.7.73,74 Whilst the 
mortality of patients in the conventional arm of 
CESAR may appear to be high for an APACHE II 
score of 20, it is comparable with that reported for 
a similar group of patients (Murray score of 3.4 and 
PaO2/FiO2 98 and APACHE II 21.5) in which the 
mortality was 67%.19 The time from randomisation 
to death was significantly shorter in the control arm 
than in the ECMO arm of the study and a higher 
proportion of patients in the control arm were 
listed as dying of respiratory failure, and it is likely 
that this explains the more rapid onset of death. In 
the ECMO arm the use of extracorporeal support 
prevents death from respiratory failure allowing 
the disease process to either recover or progress to 
fatal multisystem organ failure. It is possible that 
clinicians in the control arm withdrew care sooner 
in patients when they felt that further treatment 
was futile, whilst the ECMO team had a policy of 
withdrawing intensive care only in very selected 
cases after several weeks of attempted treatment. 
The data collected do not allow us to determine if 
there was a systematic bias to explain the difference 
in time to death between the two groups; however, 
the investigators believe that the difference is 
explained adequately by the effect of ECMO in 
supporting gas exchange and preventing early 
death from respiratory failure.
The trial design meant that the risk of bias was 
low as the clinical ECMO team was blinded to 
the outcome in the control arm; only the staff 
and members of the DMC knew the outcome in 
both arms of the study. In addition, minimisation 
criteria were used in the randomisation to ensure 
equality between the groups for variables that in 
previous series of ECMO patients had been shown 
to have an impact on outcome. This policy was 
successful in that both groups had equal numbers 
of very similar patients.
A potential limitation is the pragmatic design 
with the conventional treatment undertaken in 
43 different hospitals. This design was chosen 
as the only realistic possibility in the UK. Firstly, 
there was no funding available for treatment of 
conventional patients in a single centre. Secondly, 
there was no single unit in the UK that had the 
infrastructure to accept such an influx of patients 
allocated to CM, except for Glenfield Hospital. It 
was not, however, felt appropriate for Glenfield 
to treat all the patients in both arms. The reasons 
for this were that the Glenfield team is known to 
be enthusiastic in the use of ECMO and could 
therefore be perceived as both less committed 
to and less skilled in conventional intensive care 
management. Indeed, a number of intensivists 
stated that they did not consider the surgical ICU 
in the Glenfield ECMO unit to be competent to 
provide conventional intensive care and would not 
be willing to transfer patients to a study in which 
all the treatment for both arms was provided at the 
Glenfield Hospital. Many intensivists from CTCs 
also stated that they were unwilling to transfer 
patients out for conventional treatment in another 
hospital. In addition to these factors, the ECMO 
team felt that it would be very difficult for clinical 
staff and relatives to have patients on different 
treatments in close proximity in a study with no Discussion
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possibility of cross-over, especially if a patient was 
doing badly on a particular treatment. The trial 
team also considered the possibility of protocolising 
the conventional intensive care received by the 
control patients. The team approached the 
Intensive Care Society and also gave numerous 
presentations at regional intensive care meetings. 
Unfortunately there was no national consensus and 
no support for protocolised care. We elected to be 
pragmatic about the treatment in the control arm, 
as we knew from the previous pattern of ECMO 
patient referral that a large number of ICUs 
would be involved, thereby giving a representative 
example of ‘normal’ intensive care treatment in the 
UK. It can be argued that conventional treatment 
in a specialist centre could give improved results to 
those seen in the control arm of the CESAR study; 
this could perhaps be the focus of a future study.
Although the low volume ventilation strategy 
from the ARDSNet study was recommended for 
use by treating intensivists, it was not enforced, so 
patients in the conventional arm received many 
different approaches during their treatments. 
It is important to recognise that the patients in 
the CESAR trial were much more hypoxic than 
those in the ARDSNet study,3 PaO2/FiO2 ratios 
of 76.2 and 75.0 mmHg for ECMO and control 
groups respectively versus 138 and 134 mmHg 
for treatment and control groups respectively in 
ARDSNet. It is likely that the low compliance with 
the low volume strategy is in part because of worse 
lung disease in the CESAR patients than those 
in ARDSNet. It is possible that if CM had been 
rigorously protocolised and provided in a single 
centre or a small number of centres, the outcome 
in the control group could have been slightly 
better. However, this could have lead to bias, as the 
conventional treatment protocol would have been 
set in 1998–9 and could not have been adapted 
thereafter, so the protocol would not have included 
more recent changes in intensive care medicine 
such as activated protein C,75 sepsis care bundles76,77 
and conservative strategy of fluid management.78 
So it is also possible that a superseded CM protocol 
could have reduced survival in the control arm. By 
allowing intensivists to provide the best treatment 
that they could, we allowed adaptation of treatment 
to include recent advances and also examined 
the actual outcome of intensive care for severe 
respiratory failure in the UK.
The reality of intensive care admission for the 
majority of adult patients with respiratory failure in 
the UK is that they will not be transferred out from 
their original hospital to a larger unit however bad 
their respiratory failure is. Thus the outcome in 
the control arm should be an accurate reflection 
of prognosis for patients with severe respiratory 
failure in the majority of UK ICUs.
By nature of its complexity, ECMO treatment 
should be provided only in specialist centres. Much 
as aircraft should be flown only by suitably qualified 
pilots, the skill set required for safe provision of 
ECMO needs to be learnt over a number of years 
in an appropriately skilled ECMO centre. Almost 
every aspect of the patient and circuit management 
can result in the instant demise of the patient if 
not carried out according to established ECMO 
management protocols. It is beyond the scope 
of this monograph to include a description of 
every aspect of ECMO patient management. 
Although the Glenfield ECMO team is one of 
the most experienced in the world there was one 
complication of ECMO cannulation that resulted 
in the death of the patient. There were no other 
major complications of ECMO. This concentration 
of patients with severe respiratory failure within 
one unit may have led to an expert centre effect 
in that transferring patients to a surgical ICU that 
specialises in severe respiratory failure treatment 
could account for some of the improvement 
in outcome as the ECMO staff were more used 
to caring for patients with severe respiratory 
failure than were the referring units, and possibly 
were more used to using gentle ventilation with 
permissive hypoxia and hypercapnia when they 
knew that ECMO was instantly available should the 
patient deteriorate. The survival in the treatment 
arm was the same in the patients who were treated 
with or without ECMO. This could be because the 
clinicians correctly identified which patients did not 
require ECMO and put only the more severely ill 
on to ECMO (although it is also possible that they 
were remiss and could have obtained better survival 
by putting all the patients on ECMO). It is highly 
unlikely that survival in the ECMO arm would have 
been so good if all the patients had been treated 
conventionally by the ECMO team, unless one 
accepts the hypothesis that three cardiothoracic 
surgeons can provide better intensive care than 
that available in the majority of UK ICUs. We do 
not believe this to be the case. Indeed a recent 
study comparing intensivists and surgeons in the 
management of patients with ARDS showed that 
management of ventilation by intensivists was 
associated with a trend towards improved hospital 
survival and fewer days of mechanical ventilation 
in patients who survived.79 To paraphrase William 
of Ockham, the simplest explanation is the most 
likely to be true.80 Namely, low volume ventilation DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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has been proven to improve outcome in ARDS,3 
but patients with such severe respiratory failure 
are unable to maintain homeostasis on low volume 
ventilation, and the use of ECMO allows non-
injurious ventilator settings to be used. ECMO is 
merely a tool that allows lung rest.
The improvement in survival without severe 
disability seen in the treatment arm of the CESAR 
trial is an important real world outcome. It is 
likely that if the trial had not been designed in 
such a pragmatic fashion it would have failed 
as there were enormous changes in the NHS 
during the study, including inauguration and 
abandonment of local intensive care networks, 
a shift of commissioning of tertiary care services 
from regional health authorities to local primary 
care trusts, and implementation of the European 
working time directive legislation. The trial 
would also have failed owing to lack of patient 
recruitment if the conventional care had been 
protocolised, as UK intensivists could not agree 
protocols for national treatment when the CESAR 
protocol was being written. In addition, most 
intensivists were unwilling to consider transferring 
patients for conventional intensive care as they did 
not consider it ethical to do so.
Another important development during the study 
was the introduction of an arteriovenous carbon 
dioxide removal device (Novalung). This was used 
by one hospital on a patient in the conventional 
arm of the study, a clear protocol violation.81,82 This 
device is not equivalent to ECMO as it provides 
little oxygenation. Further studies including an 
RCT will be needed to determine its optimal use.
The policy of ECMO in the UK involved transport 
to the ECMO centre. This may be hazardous for 
patients as seriously ill as this cohort. Indeed, 
five patients in the ECMO arm succumbed before 
they could be transferred to Glenfield. Of these, 
three patients died prior to transfer and two 
died in transit, one from catastrophic pulmonary 
haemorrhage and one when the oxygen supply 
in the ambulance failed. There were no transport 
deaths in the conventional arm. All the transfers 
were carried out by the ECMO transport team 
which is specifically trained and highly skilled in 
ground and air transfer of patients with severe 
respiratory failure using conventional ventilation. 
The ventilator used was a Pneupac Ventipac® 
(Smiths Group PLC, London, UK) with the 
addition of a PEEP valve to the breathing circuit. 
The team consisted of a transport nurse, who was 
a trained ECMO specialist, in addition to a sister/
charge nurse or senior staff nurse and an ECMO 
Fellow (doctor of registrar grade), both of whom 
had been on an in-house transport course as well 
as having undertaken training transports with an 
experienced team member until considered safe 
to undertake transports ‘solo’. Ground ambulance 
was used when estimated transport time was less 
than 2 hours and rotary wing aircraft was used 
[Royal Air Force (RAF) Sea King Mk3] when a 
longer transport time was estimated and weather 
conditions allowed. Aircraft landed at the Glenfield 
Hospital helipad, speeding the transfer. One 
transport from Inverness was undertaken using 
a combination of ambulance, fixed wing aircraft 
(RAF Hercules) and helicopter. All transports 
were co-ordinated by the ECMO co-ordinator. It is 
possible that outcomes could be further improved 
by the implementation of a mobile ECMO patient 
retrieval service, as similar services have shown 
improved survival in patients transferred on ECMO 
when compared with those transferred using 
conventional ventilation prior to starting on ECMO 
at the base hospital.83,84
Economics
CESAR was one of the first multicentre trial-
based economic evaluations performed in adult 
critical care units in the UK. The CESAR trial 
was also the first RCT of adult ECMO with full 
economic support from the design stages of the 
trial, including funding for two part-time health 
economists, which helped the economic research 
team tackle many challenges in the design, 
methods, data collection, development and piloting 
of the economic questionnaire and planning of 
the analysis. The trial protocol was developed in 
collaboration with health economists, who were 
members of the Trial Steering Committee, and an 
economics working group oversaw the economic 
data collection and analysis.
Referral for ECMO has been shown in the CESAR 
trial to improve health outcomes significantly 
for adult patients with severe, but potentially 
reversible, respiratory failure when compared with 
CM. We have shown in this report, however, that 
the additional average cost per patient of treating 
this illness by transfer to the ECMO centre is more 
than double the average cost of treatment with CM. 
However, the lifetime prediction of cost–utility of 
£19,000 ($31,000) per QALY is well within those 
values regarded as affordable by many health-care 
decision-makers. The CEA Registry, published 
on the World Wide Web by Tufts University Discussion
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Medical School,85 summarises cost–utility ratios 
at 2002/3 values reported in health economic 
evaluation studies. We have chosen some of these 
values to illustrate how the cost-effectiveness of 
ECMO compares with other health technologies 
in cardiovascular and respiratory medicine. For 
example, anticoagulation therapy with warfarin 
versus none is cost saving and improves health 
for people with atrial fibrillation;86 current use 
of aspirin in patients with coronary heart disease 
aged 35–84 years costs $11,000 per QALY gained 
compared with no aspirin;87 and single lung 
transplant in end stage lung disease in the UK costs 
$51,000 per QALY gained.88 It is important to bear 
in mind when looking at such comparisons that 
the estimates from our model were based on highly 
simplified assumptions on length and quality of 
life for survivors, and that comparisons of cost-
effectiveness are subject to many methodological 
pitfalls. Further detailed research would be needed 
to build and test a robust model that takes account 
of geographical location, economies of scale and 
scope, and long-term quality of life.
The CESAR trial was funded as part of the NIHR 
HTA programme, and, during the trial, access to 
ECMO in the UK was restricted to participants in 
the trial. Findings from the trial and its economic 
evaluation will now become key information for 
the UK NHS decision-makers on whether to fund 
ECMO for adults beyond the trial setting. Although 
our study was based on the largest UK study of cost 
functions of critical care, and compared like for 
like with the costs of critical care treatment across 
the participating units, there will also continue to 
be questions to resolve about any omitted costs of 
services (such as hospital overheads or financial 
‘insurance’ costs to reflect uncertainty of predicted 
case load, which were not included in our cost 
estimates). In any business case, the final price 
agreed per case treated will alter the purchaser’s 
view of cost-effectiveness in a way that can be 
remodelled using the data from this study.
The findings are also relevant to other countries 
where ECMO is provided or being considered, 
although local costs, health services and practice 
may vary, as may travel distances (from treatment 
centres). Local economic models would need to be 
constructed to assess cost-effectiveness in different 
contexts.
We found that our hospital cost estimates were 
sensitive to critical care unit costing methods. 
National data on costs of NHS critical care were 
not available at the outset of the CESAR trial, 
but are now published as tariffs for providers 
(NHS hospital trusts)52 to use in contracts with 
third-party payers. A parallel research study 
ran alongside the trial in order to estimate the 
costs of patients according to the type of organ 
support received during their stay. Subsequent 
analysis demonstrated grouped numbers of organs 
supported on a daily basis in the critical care 
unit was the best predictor of the costs of care.63 
Although it is likely that these costs are reliable 
estimates of true resource costs, the NHS financial 
system uses different (non-case-mix adjusted) 
values that predict lower costs per outcome gained.
Not surprisingly, the cost-effectiveness would be 
improved where costs of transport and of ECMO 
provision could be reduced. These two factors 
may be inversely related. Provision of ECMO 
is likely to be most clinically and economically 
efficient (lower cost per successful case treated) 
in larger critical care units. It is also likely that 
the clinical effectiveness of smaller units would 
be reduced compared with busier units. However, 
long-distance air travel could be minimised 
with a larger number of well-placed critical care 
units, which would inevitably be smaller and less 
economically efficient. Almost all the air transport 
was provided by the RAF in the CESAR trial. This 
was relatively expensive, and the RAF does not aim 
to be a routine service provider for the NHS. Air 
transport costs may be reduced by implementation 
of a dedicated air ambulance system for patient 
retrieval. We would recommend further careful 
modelling of the most cost-effective solution for 
different settings.
The analysis reported here has taken the viewpoint 
of public sector and, especially, NHS efficiency, and 
so patient costs were not included in the analyses 
of cost-effectiveness. In the UK, health care is not 
a direct cost to patients as it is funded through 
general taxation. In other parts of the world, the 
additional costs would affect insurance financing. 
We have shown that, in the UK, costs after hospital 
discharge to patients and their informal carers were 
doubled following allocation to ECMO. Although 
most of these were not financial costs but voluntary 
time costs, there are likely to be knock-on financial 
and emotional effects. The costs for relatives of 
visiting the patient whilst in hospital were not 
directly measured for patients participating in the 
CESAR trial. However, we conducted a parallel 
study of costs of visiting intensive care in six 
participating hospitals. The results of the study 
in six centres in the CESAR trial suggested an 
average cost per single visit of around £69 at 2007 DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
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prices for out of pocket expenses. When time costs 
and income loss are included, the visiting cost is 
increased by £59 per visit. Given that the visitors 
interviewed were present daily with their relative or 
friend, the extra length of stay in the ECMO group 
suggests that visiting costs would have been much 
higher for this group than for the CM group. More 
analysis from the six CESAR hospitals participating 
in the main survey of visiting costs will be reported 
elsewhere.DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 5  
Conclusions
C
ESAR was a pragmatic trial which has 
demonstrated that a strategy of transferring 
adult patients with potentially reversible 
severe respiratory failure to a single centre for 
consideration of ECMO treatment results in a 
significant reduction in mortality and/or severe 
disability when compared with the care received 
in their original hospitals. In addition, CESAR 
has shown that this strategy is cost-effective when 
compared with other high technology life saving 
treatments such as lung transplantation. There 
were over 100 patients who could not be entered 
into the study due to lack of beds in the ECMO 
centre; a potential national adult ECMO service 
would need to be resourced to deal with all patient 
referrals. This care should also allow for needs 
of relatives and survivors at home in addition to 
the hospital and formal primary care. Estimates 
indicate that this would require an additional one 
or two ECMO centres to provide a service for 
England and Wales.
Future priorities for research should include:
•  a long-term follow-up study of CESAR trial 
patients, initially at 10 years
•  a national RCT of arteriovenous carbon 
dioxide removal (Novalung) before it becomes 
embedded in clinical practice
•  a more sophisticated model of cost–utility, 
varying value of health state at baseline, 
using longer term follow-up data and varying 
geographical and other access assumptions
•  an international multicentre RCT of ECMO as 
a treatment for respiratory failure in children.DOI: 10.3310/hta14350  Health Technology Assessment 2010; Vol. 14: No. 35
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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